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ABSTRACT
The collagen fibers that span the periodontal ligament (PDL) connect teeth to the bone
socket by weaving through the cementum of each tooth as well as into the alveolar bone.
Collagen type I is the main structural component of the PDL. High rates of extracellular
matrix (ECM) turnover are characteristic of PDL tissue. Periodontal disease (PD) afflicts
approximately 50% of the population in the United States. PD is marked by chronic
inflammation of the periodontium leading to PDL degradation, alveolar bone loss, and
eventual tooth loss. There are currently no accepted methodologies to regenerate this
collagenous PDL tissue. Thus PDL provides an excellent tissue milieu for investigating
mechanisms of collagen processing and assembly during inflammatory states that are
clinically relevant. SPARC, a collagen-binding protein, has been identified as a key
factor in collagen ECM deposition. We reported that SPARC-null mice have significantly
less total collagen, thinner collagen fibers, and reduced mechanical strength in PDL
compared to wild type (WT) PDL. A key factor in incorporation and stabilization of
insoluble collagen within the ECM is mediated through collagen cross-linking.
Transglutaminases (TGs) are a family of extracellular proteins known to participate in
collagen cross-linking activity in vitro and in vivo. Previous data implicate SPARC as a
critical regulator of TG activity on collagen I in homeostatic PDL. Inhibition of TG
activity in vivo was shown to reverse SPARC-dependent decreases in collagen volume
fraction and mechanical strength of homeostatic PDL. Our data predicts SPARC
regulates TG activity by mediating substrate specificity in the ECM.
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CHAPTER 1: INTRODUCTION
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1. Periodontal ligament collagen
The periodontal ligament (PDL) is the collagenous tissue that anchors tooth root
cementum into underlying alveolar bone. The principle components of the PDL are blood
vessels, fibroblasts, and collagen fibers.

Fibroblasts, the most common cells of

mammalian connective tissue, are the main cell type responsible for synthesizing and
secreting extracellular matrix (ECM) and collagen to maintain the structural integrity of
the PDL. Collagen is the most abundant protein in the human body and makes up 25% to
35% of whole-body protein content; 90% of which is composed of collagen type I [1].
One of the major characteristics of PDL collagen is its exceptionally high rate of
turnover, making the PDL an ideal tissue to investigate mechanisms of collagen assembly
and incorporation into the ECM [2]. Fibrillar collagens, particularly types I (~75%), III
(20%), and V (5%), are the major components of PDL providing tensile strength and
stability [3]. Additionally, non-fibrillar collagen types IV, VI, XII, and XIV are also
present in minor amounts within the PDL [4]. Fibrillar collagens are highly glycosylated
and surrounded by water, hyaluronic acid, and proteoglycans which provide resistance
against compressive forces within the periodontal ligament ECM [5].
Collagen type I is the most abundant type of collagen in the collagen superfamily
(made up of 28 family members) and the main structural component of murine and
human PDL. Type I collagen is a heterotrimeric helical molecule comprised of two α1
chains and one α2 chain. The right-handed helix of type I collagen is approximately 300
nm long, 1.5 nm in diameter, and has a distinct amino acid arrangement of Glycine-X-Y,
where X and Y are frequently Proline and Hydroxyproline, respectively. Glycine is found
at almost every third residue of collagen I, and proline makes up about 17% of type I
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collagen. Hydroxyproline, derived from the hydroxylation of proline residues, and
hydroxylysine, derived from lysine, are modified post-translationally by prolyl-(3,4)hydroxylase enzymes. Proline and hydroxyproline act to stabilize the super coils of the
triple helices of individual polypeptide strands of the collagen molecule in a favorable
entropic and stable thermal state [6]. The complete absence of prolyl hydroxylation in
animal models results in lethality [7].
The synthesis of the collagen molecule (Fig. 1) begins with mRNA transcription of
genes associated with specific collagen alpha peptide (1, 2, or 3) formation (34 COL
genes). Once the mRNA exits the fibroblast nucleus it associates with the ribosomal
subunits in the cytoplasm to begin the process of translation. The newly formed trimeric
protein is known as the pre-pro-peptide with N- and C-terminal propeptides. The Cterminal propeptide is implicated in collagen alpha chain recognition, that takes place in
the endoplasmic reticulum, and in collagen I solubility [8]. The N-propeptide of collagen
I, particularly encoded in exon 2 of the COL1A1 gene, has also been proposed to
contribute to collagen I solubility. However, the precise functional role of the N-terminal
propeptide is poorly understood and thus is a central subject of examination in Section 1
of Chapters 3 and 4. The signal sequences on the N- and C-terminal propeptides are
recognized by signal recognition particles on the endoplasmic reticulum (ER), which are
responsible for directing the pre-pro-peptide into the ER for post-translational
modification where it is now known as pre-pro-collagen. The pre-pro-collagen molecule
is modified by the addition of hydroxyl groups to the amino acids proline and lysine by
hydroxylase enzymes prolyl-4-hydroxylase and lysyl-hydroxylase.
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Figure 1. Collagen Synthesis. PDL collagen type I undergoes complex collagen fiber
assembly. The figure outlines the sequential processes involved in formation of a
mature collagen fiber. N-propeptide function and intra-molecular cross-linking of
collagen I in the extracellular matrix are investigated.
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Both hydroxylase enzymes require ascorbic acid (vitamin C) as a cofactor and work to
aid in cross-linking of the alpha peptides [9]. Deficiency of ascorbic acid, typically
associated with scurvy, results in the lack of hydroxylation of prolines and lysines
causing the formation of a loose collagen triple helix. Patients suffering from scurvy
often develop gingival ulcerations and rapid tooth loss [10]. Hydroxylation is an
important precursor step that allows for subsequent glycosylation to occur. Glucose or
galactose monomers are added onto hydroxyl groups on lysines, but not prolines, during
glycosylation. The formation of the triple alpha helical structure inside the RER,
composed of two hydroxylated and glycosylated alpha-1 chains and one alpha-2 chain,
are transported to the Golgi apparatus as a procollagen molecule for packaging and
secretion. Procollagen undergoes one final post-translational modification in the Golgi
apparatus where oligosaccharides are added prior to excretion into the extracellular space.
Procollagen molecules are transported outside the cell with assistance from collagenbinding proteins, which behave as chaperones to facilitate exocytosis. Collagen-binding
proteins are critical in collagen fibril synthesis, fiber assembly, and collagen deposition
into the ECM. Once outside the cell, the terminal N- and C- propeptides are cleaved by
procollagen peptidase enzymes resulting in the formation of a tropocollagen molecule
[9]. Defects in the formation of tropocollagen result in the collagenopathy Ehlers-Danlos
syndrome. Patients with Ehlers-Danlos syndrome exhibit a wide range of oral
manifestations including luxations of the TMJ, gingival fragility, excessive hemorrhage
during dental procedures, early-onset periodontitis, and enamel hypoplasia [11].
Additionally, several other disorders associated with collagen mutations manifest with
severe oral complications (Table 1). Multiple tropocollagen molecules assemble by the
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formation of covalent bonding facilitated by cross-linking enzymes (lysyl oxidase and
transglutaminase) to form collagen fibrils. Multiple collagen fibrils aggregate to form
mature collagen fibers and attach to cell surfaces through transmembrane receptors such
as integrins and glycoproteins such as fibronectin [9].
Individual collagen fibrils of the PDL are organized into fiber bundles, which span
the width of the PDL and are the only non-mineralized fibers to connect two distinct hard
tissues (tooth and bone) in the mammalian body. The terminal ends of PDL collagen
bundles are embedded in the alveolar bone and tooth cementum and form partially
mineralized Sharpey’s fibers [12]. Individual collagen fibrils are continuously remodeled
by fibroblasts at a rapid rate in the PDL demonstrating a half-life of 2 – 12 days in
various animal species [13, 14]. Tissue accessibility and high collagen turnover rate and
content make the PDL an ideal tissue for better understanding mechanisms of collagen
assembly, stabilization, and regeneration applicable to a variety of collagen-rich tissues.

2. Degradation of fibrillar PDL collagen during PD
Periodontal disease (PD) is a chronic inflammatory condition initiated by the
formation of a bacterial biofilm colonizing the tooth surface and periodontal pocket (Fig.
2). Keystone pathogens colonizing the bacterial biofilm are activated and initiate an
immune response in the local environment. Initial influx of immune infiltrate to local site
of inflammation is exasperated by host immune response and inability to clear immune
cells. Chronic inflammation of PD in tissues of the periodontium (tooth, PDL, alveolar
bone) leads to progressive degradation of PDL collagen fibers, loss of alveolar bone
volume, and eventual tooth loss.
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Table 1. Diverse Oral Manifestations of Collagen-Associated Disorders
Collagen
Associated
Disorder

Mutated Collagen
Gene

Oral Manifestations

Scurvy

N/A

•
•
•
•

Halitosis
Ulcerative; hemorrhagic gingival tissue
PDL degradation
Premature loss of dentition [15]

Oral Submucous
Fibrosis

N/A

•
•
•
•
•
•
•
•
•

Xerostomia
Oral mucosa pigmentation
Thinning & tightening of lips
Oral epithelial atrophy
Tongue papilla atrophy
Recurrent ulceration
Restricted soft palate
Shrunken uvula
Restricted oral aperture & tongue protrusion [16]

Systemic Lupus
Erythematosis
(SLE)

N/A

•
•
•
•
•
•

Xerostomia
Oral ulcerations, erythema, hyperkeratosis
Stomatodynia
Candidiasis
PD
Dysgeusia [17]

Sjogren’s Syndrome

N/A

•
•
•

Xerostomia
Early onset caries
Enlarged salivary glands [18]

Scleroderma

N/A

•
•
•
•
•
•
•
•
•
•

Xerostomia, microstomia, telangietasia
Gingival recession
Increased tongue rigidity
Pseudoankylosis of TMJ [19]
Restricted oral aperture
Loss of PDL integrity
Radiographic widening of PDL space
Increased risk of PD development
Mandibular bone resorption
Tooth root resorption [20]

Ehlers-Danlos
Syndrome

•
•

•
•
•

Gorlin sign
Absence of inferior labial and lingual frenula
Gingival fragility; excessive hemorrhage during
dental procedures
Early onset PD; premature loss of dentition [21]

COL5A1
COL5A2

•
Osteogenesis
Imperfecta

•
•

COL1A1
COL1A2

•

•

Dentinogenesis Imperfecta: dentin dysplasia, DEJ
scalloping, enamel fracturing & loss, caries,
periapical abscesses, pulp chamber obliteration,
irregular dentinal tubules [22]
Class III malocclusion [23]
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Stickler Syndrome

•
•

COL2A1
COL11A1/2

•
•
•
•
•

Malocclusion
Micrognathia
Glossoptosis
Bifid uvula
Cleft palate [24]

Alport Syndrome

•

COL4A3/4/5/6

•

Gingival overgrowth [25]

Chondrodysplasia
Punctata

•

COL2A1

•
•
•

Enamel hypoplasia
Reduced dental arch length & tooth size
Maxillary & mandibular growth attenuation [26]

Epidermolysis
Bullosa

•

COL7A1

•
•
•
•
•
•
•
•

Enamel hypoplasia
Ankyloglossia
Lingual depapillation
Palatal rugae & tongue atrophy
Intraoral ulcerations & bullae formation
Microstomia
Absence of buccal & vestibular sulci
Early onset caries [27]

Knobloch Syndrome

•

COL18A1

•
•
•
•
•

Xanthogranuloma
Labial nodular lesions
Fibrotic frenae
Orthopantomograph
Frequent enamel fractures; exaggerated Retzius
lines
Rotated incisors
DEJ scalloping
Early onset caries
Mulberry molars [28]

•
•
•
•

*disorders are listed in order of prevalence
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Maintaining the integrity of the PDL collagen fibers and restoring these structures
following disease treatment are essential for maintaining a healthy dentition [29].
Collagenous ECM turnover occurs in homeostatic tissues through a balance of matrix
breakdown, resorption, and remodeling. Pathological conditions characterized by
accelerated breakdown of connective tissue, such as PD, are a failure of normal
regulatory mechanisms. Periodontal pathogens stimulate cytokine production (IL-1β,
TGF-β) and prostaglandins (E2) in response to a bacterial endotoxin lipopolysaccharide
(LPS) that, in turn, induces matrix metalloproteinase (MMP) synthesis by resident
gingival immune cells [30]. MMPs are a family of 25 proteinases capable of digesting
macromolecules of tissue matrices including collagen. Of particular interest in the PDL is
the collagenase group of MMPs (1, 8, 13, 18) and the gelatinase MMPs (2 and 9), which
are the only known mammalian enzymes capable of degrading fibrillar collagens [31].
MMP collagen-binding domains facilitate interaction between enzyme and collagen
substrates. MMP binding along collagen fibrils facilitates neutrophil migration, and cell
movement on collagen via integrins, and induction of cytoskeletal rearrangement [32].
Inter-domain flexing occurs between collagen-binding domains of MMPs and facilitates
bending of collagen peptide and unwinding/cleavage of triple helical collagen [33].
Elevated levels of MMP-2 and -9 mRNA are associated with PD severity in human
subjects [34]. Tissue inhibitors of MMPs (TIMPs), secreted by most connective tissue
cells and macrophages, form high-affinity, non-covalent complexes with active forms of
MMPs to control their activity. Decreased human salivary levels of TIMP-1 mRNA are
correlated with PD states compared to healthy controls [35].
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Figure 2. Tissue Destruction in PD. Representation of bacterial biofilm
colonization into the oral epithelial-tooth interface. As periodontal pocket develops
plaque antigens stimulate neutrophil and monocyte activation to produce cytokines
and MMPs causing loss of PDL attachment, degradation of collagen fibers, and
alveolar bone destruction by stimulated osteoclast activity.
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Recent clinical trials have utilized antibiotic cocktails with MMP inhibitory activity,
following periodontal treatment, to restore the imbalance between MMPs and TIMPs to
homeostatic levels [36]. While the resolution of MMP and TIMP balance in the PDL aids
in faster resolution of local inflammatory response, it does not restore damaged/degraded
tissues; it attenuates disease progression. Additionally, the development of antibiotic
resistance has raised concern about long-term use of such treatments to manage the
chronic inflammation of PD [37].
To date, available treatment options for PD are limited (Fig. 3). Initial treatment
begins with clearance of biofilm causing plaque and calculus through scaling and root
planing. Loss of periodontal tissue structure from advanced, chronic PD is treated with
surgical intervention involving gingival flap surgery and tissue and bone grafts combined
with antibiotic therapy to attenuate further tissue loss. Long-term success rates of soft and
hard tissue grafts have been unreported and seem to depend largely on severity of disease
state and patient-specific confounding factors [38]. Once, PD has progressed to tooth
loss, the only treatment to prevent further resorption of the alveolar bone is to replace the
structure with a metal/zirconium implant. Implant placement involves direct contact of
implant with alveolar bone without a soft tissue intermediary to absorb/distribute forces
of mastication, which is implicated in the high 10-year failure rate of 50% [39].
Periodontal surgery treatments do not recover or restore PDL collagen state; similar to
other PD therapies, surgery simply attenuates the disease state at the present stage.
Methods of collagen regeneration are the focus of many studies aimed at restoring
collagen-rich tissues following disease destruction.
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Figure 3. PD Progression & Current Therapeutic Interventions. Degradation of PDL
collagen fibers due to PD directly leads to resorption of alveolar bone and tooth loss in
patients. Current therapies can attenuate PD only once diagnosed. Upon diagnosis
significant collagen composition of the PDL has already been permanently degraded. A
better understanding of mechanisms of collagen assembly and stability in the ECM of the
PDL will provide insight into novel regenerative therapeutics to replenish total PDL
collagen.
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3. SPARC maintains collagen I content in the ECM of the PDL during homeostasis
Secreted protein acidic and rich in cysteine (SPARC/osteonectin/BM-40) is a 40kDa
collagen-binding matricellular glycoprotein whose expression is closely aligned with that
of fibrillar collagens such as collagen type I. SPARC is most highly expressed in ECM of
tissues during states of collagen deposition: embryonic tissues development, wound
healing, tissue turnover, and fibrotic disease states [40]. Many cell types including
endothelial cells [41], fibroblasts [42], pericytes [43], osteoblasts [44], and macrophages
[45] express SPARC. SPARC plays a vital role in tissue mineralization, cell-matrix
interactions, collagen binding, angiogenesis, and cell migration. Unlike other
matricellular proteins such as thrombospondin and tenascin, SPARC is anti-adhesive and
inhibits cell spreading and proliferation [46]. The single polypeptide chain of SPARC is
composed of four domains: 1. an extracellular calcium-binding (EC) domain near the
glutamic acid-rich region located at the amino terminus, 2. a cysteine-rich domain, 3. a
hydrophilic region, and 4. an EF hand motif located at the carboxy terminus [47].
Evidence that SPARC binds fibrillar collagens I, III, and V via its EC domain in addition
to basement membrane collagen IV, implicate SPARC in the assembly of connective
tissue ECM as well as basement membranes [40].
ECM collagen assembly and the activity of TGF-β1 are both influenced by SPARC
expression. TGF-β1 is a cytokine known to stimulate the synthesis of collagen type I and
increase SPARC expression [42]. In a reciprocal manner, addition of exogenous SPARC
to mesangial cells in vitro, resulted in TGF-β1 induction and collagen I synthesis [48].
Reductions in SPARC expression, mediated by siRNA silencing, decreased TGF- β1
expression in cultured human fibroblasts. Since TGF-β1 is considered a profibrotic
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cytokine, the ability of SPARC to regulate TGF-β pathways implicates SPARC in
controlling fibrotic tissue states [49].
Examination of SPARC-null mice is highly useful in understanding ECM synthesis
and collagen assembly. The SPARC-null mouse is well established and utilized in a
number of experimental studies. The global abrogation of SPARC expression in
transgenic mice most frequently utilized is created by the deletion of exon 4 in the
SPARC gene [50]. Upon gross examination, SPARC-null mice appear phenotypically
similar to their WT counterparts with the exception of a curly tail [51]. Abrogation of
SPARC in mice does not affect body weight or lifespan. However, these mice develop
premature cataracts, as early as 1.5 months of age, due to deficient lens epithelial cell
formation of basement membranes [50]. A number of other abnormalities detected in
SPARC-null mice are manifested in ECM structure and function, implicating the
important role of SPARC in collagen assembly and deposition.
A lack of SPARC expression has been shown to diminish mature collagen
accumulation in the ECM of many connective tissues including PDL [40, 52]. SPARCnull mice exhibit decreased total collagen I content in the PDL in addition to other tissues
(tendon, dermis, cardiac). Likewise, there is diminished deposition of fibrotic collagen in
PDL tissues in the absence of SPARC. Studies have shown a correlation between
increased levels of SPARC expression and stimulated increases in collagen deposition
and assembly into the ECM [53]. Increases in soluble collagen in SPARC-null mice also
suggest that incorporation of collagen into insoluble collagen fibrils is not efficient in the
absence of SPARC [54]. Studies performed in fibroblasts have suggested that SPARC
acts to facilitate procollagen processing by limiting procollagen association with cell
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surface receptors [55, 56]. The SPARC binding site on collagen overlaps with that of the
collagen receptor Discoidin Domain Receptors (DDR) 1 and 2 [57]. Hence, SPARC
bound to collagen I might limit binding to cell surface DDR2 and therefore decrease
signaling initiated via DDR2 as well as possibly allowing for more efficient incorporation
of collagen into insoluble ECM. Speculatively, increased interaction of soluble collagen
with DDR2 in the absence of SPARC might tether procollagen at cell surfaces leading to
increased turnover of collagen at the cell surface at the expense of collagen deposition
into the ECM.
Previous studies from our laboratory have examined the function of SPARC in
collagen homeostasis specifically to maintain healthy murine PDL from development
through adulthood (summarized in Table 2). Expression patterns of SPARC were
distinguishable in murine PDL at all age points (1, 4, 6, and >18 months), with robust
increased expression in developing 1 month PDL and aging >18 month PDL; age points
which both correlate with increased ECM turnover and remodeling. Homeostatic adult
PDL displayed baseline expression levels of SPARC [58]. Results of SPARC expression
in PDL correspond to elevated levels of expression during development, ECM
remodeling, and wound healing reported in other tissues (dermal, cardiac, tendon) [55,
59-62]. Fibroblast cell population was decreased in young, 1-month PDL in the absence
of SPARC but remained constant in WT PDL. It was postulated that fibroblasts in the
absence of SPARC had delayed migration from dental follicle to alveolar bone compared
to WT counterparts resulting in decreased cell nuclei populating the PDL of these mice.
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Table 2. Summary of Homeostatic PDL Alterations in the Absence of SPARC [58]
Murine PDL Age
Characteristic

Genotype

1 month

4 months

6 months

>18 months

SPARC expression

WT

High

Low

Absent

High

Fibroblast population

WT

80%

80%

88%

98%

SPARC-null

70%

85%

86%

92%

WT

Low

Low

Low

Moderate

SPARC-null

Moderate

Moderate

High

Absent

WT

75%

80%

75%

78%

SPARC-null

67%

64%

72%

50%

WT

60%

64%

71%

65%

SPARC-null

54%

50%

62%

38%

Interstitial space

Collagen I content

Thick fiber content

29

However, increasing age points restored fibroblast cell population in SPARC-null PDL
until >18 months when cell population decreased again. Total collagen I content as well
as thick fiber content in SPARC-null PDL was significantly decreased compared to WT
PDL at all age points but was most robust at 1- and >18-month age points. The increased
number of fibroblast cell nuclei at 1- and >18- months might indicate a compensatory
mechanism in an attempt for the PDL to restore the exacerbated loss of collagen fibers at
these time points. Additionally, these time points correlate to the highest levels of
SPARC expression in the PDL. The authors propose the absence of SPARC gives rise to
increased collagen turnover at fibroblast cell surfaces resulting in inefficient collagen
incorporation to insoluble ECM, decreased total collagen I content, and smaller fibers in
homeostatic murine PDL at various age points [58].

4. Function of SPARC in mineralized tissue
At one time SPARC was thought to be expressed specifically in mineralized tissues
(thus the name osteonectin) but was subsequently demonstrated to have a much wider
expression pattern in both mineralized and non-mineralized tissues (summarized in Table
3) [63]. The protein component of the pre-mineralized bone matrix (osteoid) is composed
mainly of collagen type I (94%) and a number of noncollagenous proteins. The
mechanical properties of bone are largely attributed to the mineral composition of the
osteoid in the form of hydroxyapatite (HA) - a complex of calcium and phosphate - that
mineralizes the collagenous matrix. Generally, calcified bone is comprised of ~ 70% HA,
25% matrix, and 5% water [64]. SPARC contains both a collagen-binding domain and an
HA binding region [63].
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Table 3. Activities attributed to SPARC in mineralized and non-mineralized cells
and tissues.
In vitro

In vivo

Collagen
production

SPARC-null fibroblasts (fb):
No change in levels of mRNA for
collagen I [53]

Collagen
assembly

SPARC-null fb:
Altered procollagen processing
écell surface-associated collagen
[55, 56]

Mineralization

SPARC Peptide ON29:
êapatite crystal H2O content [69]
êphosphate content [69]

SPARC-null tissues:
No change in levels of mRNA for collagen I [65]
é soluble collagen [54]
êtotal collagen content [53]
êfibrotic collagen [53]
SPARC-null PDL:
ê collagen content, smaller collagen fibers [58]
éTG activity on collagen I [66]
éTG collagen crosslinks [66]
SPARC-null bones:
écollagen content [67]
écollagen maturity [67, 68]
Larger, less uniform fibril diameters
SPARC-null bones:
émineral content [68]
écrystal size [68]

Bone
properties

N/A

Osteoblasts

SPARC expressed by
differentiating osteoblasts,
Regulated by miR29 [74]
SPARC-null bone-marrow derived
cells:
êOB precursor cells [75]
éadipocytes differentiated in
vitro [75]
êmineralized OB nodules [75]
Do not express SPARC
SPARC-null cells:
éPTH effect on
osteoclastogenesis [76]

Osteoclasts

SPARC-null bones:
êbiomechanical properties: 3-point bending of
femur [67]
êbone turnover rate [67]
êlong bone length [70]
é early-onset trabecular osteopenia [67]
Normal cortical area, ê cortical fragility [70]
émineral content
écrystal size
éadiposity of bone marrow [70]
é intervertebral disc degeneration [71]
Missense (GèR) mutation in gene encoding
SPARC disrupts collagen binding pocket è
severe OI [65]
SNP1599 of 3’UTR SPARC è idiopathic
osteoporosis - êSPARC,êdeposited matrix,
êcortical bone area, ê trabecular bone with
age [72, 73]
SPARC-null bones:
êbasic multicellular units (BMUs) [67]

SPARC-null bones:
OC numbers éwith PTH stimulation [76]
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In the osteoid, SPARC has been proposed to bind collagen and HA crystals and release
calcium ions perhaps enhancing mineralization of the collagen matrix in bones [52]. The
function of SPARC in mineralized tissues both during homeostasis and disease has yet to
be fully defined, however a significant amount of insight into SPARC activity in
mineralized tissues has emanated from analysis of SPARC-null mice and identified
mutations in the gene encoding SPARC in human disease (Fig. 4).
SPARC is encoded by a single gene, on chromosome 5 (5q31 – q33) that generates a
secreted, monomeric, glycosylated polypeptide. SPARC has four defined domains: 1) an
N-terminal low-affinity, high capacity, calcium-binding domain that contains the mineral
binding region, 2) a Cysteine-rich domain, 3) a hydrophilic region, and 4) an extracellular
Ca2+ (EC) domain with an E-F hand motif at the C-terminus that encompasses the
collagen binding domain. The helix-loop-helix structure (EF hand motif) is a domain
characteristic of some calcium-binding proteins and is composed of two alpha helices and
one short loop region [77]. SPARC is a glycoprotein shown to undergo differential
glycosylation dependent upon tissue-specific expression. Importantly, the glycosylated
form of SPARC, expressed in bone, binds collagen with higher affinity than the form
found in platelets [78].
SPARC is secreted by osteoblasts in bone during bone formation [44]. The collagenbinding domain of SPARC, at the C-terminus is separated from the hydroxyapatitebinding site at the N-terminal region. The separation of these two interacting domains has
been predicted to facilitate mineralization of collagen during bone formation [52].
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Figure 4. SPARC activity in the formation of mineralized matrix. Critical steps
in bone formation include: 1) osteoblast differentiation 2) procollagen secretion 3)
procollagen processing 4) mineral incorporation, and 5) collagen cross-linking.
Steps shown with yellow boxes are processes regulated by SPARC that potentially
influence bone formation based on results from cells and/or non-mineralized
tissues. Steps shown in red boxes are processes shown to be altered in SPARC-null
bones.
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Similar to patterns of SPARC expression in other tissues, levels of SPARC are high in
immature bone and are associated with mineralization of collagen whereas a decrease in
SPARC expression is observed in mature bone homeostasis [44]. Notably, SPARC is
expressed at high levels in osseous tissue with high turnover such as in active osteoblasts
and bone marrow progenitor cells, odontoblasts (dentin-forming cells), periodontal
ligament fibroblasts, hypertrophic chondrocytes, and osteoid [44, 58, 63, 78, 79]. SPARC
is not only synthesized by osteoblasts, but also by endothelial cells and fibroblasts present
in mineralized tissues [41].
Initial characterization of SPARC-null mice indicated no overt phenotypic differences
in skeletal development in the absence of SPARC [80]. However, subsequent studies
have revealed significant differences in the bone phenotype in SPARC-null versus WT
mice. SPARC-null mice have a curly tail, demonstrate decreases in bone mineral density,
develop low-turnover osteopenia at an early age, and exhibit slight decreases in the length
of femur long bones [65]. Despite these phenotypic abnormalities, the absence of SPARC
expression does not significantly influence lifespan, reproduction, or overall body weight.
Similar to connective tissue, skeletal defects in SPARC-null mice were most pronounced
under conditions of active bone remodeling. For example, SPARC-null mice develop
accelerated intervertebral disc degeneration [74, 81]. In addition, whereas WT mice
exhibit significant increases in bone mineral density in response to bone-anabolic
parathyroid hormone treatment, SPARC-null mice do not [82].
The first reported skeletal phenotype in SPARC-null mice was early onset osteopenia
[83]. Osteopenia is characterized by decreased bone mineral density and is considered by
some clinicians to be a precursor to osteoporosis. The osteopenia indicative of SPARC-
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null mice became progressively worse with age. At 11 weeks, radiographic differences in
trabecular bone density of femurs were detected in SPARC-null versus WT mice. By 17
weeks of age, differences in bone density impacted femur bone strength as SPARC-null
bones demonstrated reduced biomechanical properties versus WT bones measured by the
3-point bending test. Whereas WT bones gained strength from 11 to 17 weeks, the bones
of SPARC-null mice did not as evidenced by lower measured maximum load (N),
maximum displacement (mm), and stiffness (N/mm) [83]. SPARC-null mice have
decreased numbers of osteoblasts and osteoclasts and an ~50% reduction in boneformation rates [83]. SPARC-null tibia 17 weeks had 50% less trabecular bone volume
compared to WT tibia as indicated by decreases in trabecular number and increases in
trabecular spacing quantitated by histomorphometric measurements. Trabecular bone
volume of SPARC-null tibia decreased further with age (36 weeks) to 70% less than WT
trabecular bone volume [83]. Frequently, decreased bone formation in both the trabecular
and cortical bone compartments is characteristic of osteopenia. Interestingly, in SPARCnull mice, osteopenia was primarily observed in trabecular bone where bone resorption
was greater than bone formation leading to a decrease in bone mass that was compounded
over time. Trabecular bone is frequently more affected in deficiencies characterized by
reduced bone mineral density and SPARC expression was more readily detected in
extracts from trabecular versus cortical bone [52].
The osteonectin 3’ UTR has two identified haplotypes associated with bone mineral
density (BMD): A and B. Haplotype A is found at a higher frequency in severe
osteoporotic patients demonstrating decreased BMD, whereas haplotype B is more
commonly associated with healthy controls and higher BMD levels. A single nucleotide
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polymorphism (SNP1599) in the 3’ untranslated region of SPARC has been shown to
associate with reduced bone volume in patients with idiopathic osteoporosis [84].
Specifically variants SNP1599G found in haplotype A and 1599C found in haplotype B
were compared. To discern whether SNP1599C/G influenced the expression of SPARC
in vivo, mice carrying SNP1599C/G were genetically engineered [85]. Mice carrying the
SNP1599G variant deposited less mineralized matrix, less cortical bone area, less
trabecular bone volume with age, and decreased overall bone formation rates in
comparison to mice carrying SNP1599C variant and to control mice. Increased cortical
bone area in response to intermittent PTH treatment was less in mice with SNPS1599G
than that of 1599C variant mice. SNP1599G introduced a novel miR-433 binding site in
the 3’UTR of SPARC [85]. The 3’ UTR of many mRNAs is known to have regulatory
effects on gene expression through modulation of mRNA stability, targeting, and/or
translation. Accordingly, SNPs within the SPARC 3’UTR might influence synthesis of
SPARC and contribute to variations in expression patterns among individuals. During
osteoblast differentiation, the expression of miR-433 decreases and inhibitors of miR-433
promote osteoblast differentiation [85]. Hence miR-433 is predicted to act as an inhibitor
of osteoblast differentiation. SNP1599G osteoblasts were shown to have defects in
differentiation both in vitro and in vivo. SPARC expression levels were decreased by the
inclusion of SNP1599G, presumably through inhibition mediated by miR-433 [85].
Closer examination of SPARC-null bones has revealed specific alterations in collagen
structure, mineral composition, and apatite crystallite morphology in comparison to WT
bones [67]. In line with a low bone turnover rate in the absence of SPARC, higher
mineral contents and increases in crystal size were found in SPARC-null bones. In
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addition, infrared microspectroscopic measurements of SPARC-null cortical bone
collected from three dimensions of tibia revealed decreased rates of bone formation
despite the absence of differences in overall cortical thickness versus WT bones [67].
Hence, SPARC-dependent defects in trabecular bone formation were also observed in
cortical bone. Likely, elevated mineral content and highly cross linked matrix generated
by slow turnover in the absence of SPARC maintained cortical bone thickness whereas
overt decreases in trabecular bone density were more easily detected. Nonetheless,
mechanical properties of cortical bone were weakened in SPARC-null mice demonstrated
by increased bone fragility despite normal cortical area [83]. Synthesis of mRNA
encoding collagen I subunits along with other ECM proteins associated with bone
formation were not significantly altered in SPARC-null versus WT mice at 17 weeks of
age [83]. Hence, although basic multicellular units (BMUs), the functional unit
comprised of osteoblasts and osteoclasts, were reduced in the absence of SPARC,
decreases in collagen synthesis did not appear to significantly contribute to reductions in
bone matrix remodeling.
SPARC might also influence bone formation through its capacity to bind mineral. In a
recent study, a peptide (ON29) derived from the mineral-binding region of SPARC
induced changes to the disordered phase and apatite crystallite morphology in an in vitro
assay of matrix mineralization [70]. Apatite embedded with ON29 revealed significant
decreases in the amount of water molecules in the disordered phase of crystal
mineralization and reductions in phosphate content, however calcium content remain
unchanged [70]. Decreases in phosphate levels altered the disordered phase of apatite
crystal growth by inducing needle-like crystal morphology in culture as opposed to plate-
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like morphology. Decreased hydroxyl transfer to the disordered phase was observed with
peptide treatment, but overall mineral transfer was unaffected [70]. Hence, some aspects
of the altered phenotype of SPARC-null bones might arise from deficiencies in crystal
mineralization, specifically in the disordered interface, that in turn might influence
turnover rates of bone.
Osteogenesis imperfect (OI) is a heritable bone fragility disorder most frequently
caused by mutations in genes encoding collagen 1α(I) or collagen 2α(I) subunits [71].
Osteoblasts from patients with OI have been reported to display decreased amounts of
total collagen, SPARC, and proteoglycans as well as defects in metabolism [68, 69].
Whether the decreased levels of SPARC are a result of abnormal OI bone matrix or
whether decreased levels of SPARC contribute to this disease phenotype is not resolved.
Recently, mutations in the gene encoding SPARC were identified in two individuals with
recessive OI using whole-exome sequencing [86]. Both of the effected individuals
demonstrated severe bone fragility and early-onset scoliosis. The mutations in the gene
encoding SPARC in individuals with OI were found to be glycine to arginine missense
mutations in exon 7 from one individual and in exon 9 from the second individual [86].
The sequence of the collagen-binding site in SPARC is characterized as a “phenylalanine
(Phe) pocket”. Arg166 and Glu263 are conserved amino acids in the extracellular Ca2+
(EC) binding domain of SPARC. These amino acids form a salt bridge necessary for
collagen binding in the “Phe pocket”. Mutations in Arg166 or Glu263 disrupt the pocket
and significantly reduce SPARC affinity for collagen I. Hence, the collagen-binding
function of SPARC is hypothesized to play a critical role in collagen deposition in bone.
Dermal fibroblasts isolated from individuals with SPARC mutations associated with OI
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exhibited kinetic differences in collagen I triple helical assembly including delayed
procollagen I secretion [86]. Despite phenotypic similarities, the recent study
distinguished OI caused by mutations in the gene encoding SPARC from previously
characterized OI type VI.

SPARC was thus identified as one of the known non-

collagenous proteins in which mutations can cause a severe form of OI.
SPARC is expressed by osteoblasts undergoing active matrix deposition.
Interestingly, during in vitro differentiation of osteoblasts in WT cells, SPARC mRNA
levels remain relatively constant [87]. However, levels of SPARC protein were shown to
increase during the matrix deposition phase of osteoblast culture differentiation. Levels of
SPARC protein are highest at times coinciding with initial stages of differentiation and
subsequently decrease as cells mature and begin to express mature osteoblast markers
[87]. The differences in expression of SPARC protein versus mRNA suggested a
significant role for post-transcriptional regulation of SPARC in osteoblasts. Notably,
SPARC mRNA has a significantly long half-life, which would be predicted to affect the
efficacy of transcriptional regulation as a primary mediator of expression. Regions in the
3’UTR of SPARC mRNA contain highly conserved sequences that interact with miR29.
Kapinas et al, presented strong evidence that post-transcriptional regulation of SPARC
mRNA by members of the miR-29 family was a primary mechanism by which levels of
SPARC were regulated in osteoblasts. Increased levels of miR-29 during osteoblast
differentiation correlates with decreased amounts of SPARC protein levels [87].
Delany et al. have reported that osteoblast precursors were reduced in SPARC-null
mice and that induction of osteoblast differentiation from SPARC-null bone marrow
derived cells was impaired [88]. Cell populations isolated from SPARC-null bone
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marrow demonstrated fewer osteoblast cells when grown under conditions favoring
osteoblastogenesis. Concomitantly, a higher number of adipocytes were detected in
SPARC-null versus WT cultures in which SPARC-null cells expressed higher levels of
adipsin mRNA, a marker of mature adipocytes [88]. Interestingly, diminished cell
survival also indicative of SPARC-null bone marrow derived cells was rescued by
reintroduction of SPARC expression through transfection of SPARC-expressing vectors
but not by incubation with recombinant SPARC protein. SPARC-null osteoblasts,
differentiated in vitro, showed similar levels of osteoblast differentiation markers:
osteopontin and bone sialoprotein. Significantly lower levels of osteocalcin mRNA were
detected versus WT cells. In addition, attenuated formation of mineralized nodules was
observed in SPARC-null cultures that suggested that SPARC-null osteoblast do not
undergo a complete process of maturation [88]. Hence, cultures derived from SPARCnull mice displayed a higher propensity for the differentiation of adipocytes at the
expense of competent osteoblast differentiation. Interestingly, an increase in adiposity of
SPARC-null bone marrow has also been described [89].
Parathyroid hormone (PTH) is a potent stimulator of bone remodeling that supports
formation of new bone over those processes that influence bone resorption. Presently,
intermittent administration of PTH is the most commonly used bone-anabolic therapeutic
option for osteoporosis patients. To test whether SPARC might influence PTH efficacy,
WT and SPARC-null mice were treated with PTH and assessed for differences in bone
formation [82]. As expected, PTH treatment elevated whole body bone mineral density in
WT mice however, notably, no increases in bone mineral density were observed in
SPARC-null mice. Although the osteoblast response was similar in WT and SPARC-null
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mice treated with PTH, SPARC-null mice had a significant increase in the number of
osteoclasts and the associated eroded surface of bone in comparison to WT mice treated
with PTH [82]. PTH treatment is known to result in the formation of multinucleated
osteoclasts through the increase in expression of RANK-ligand accompanied by a
decrease in osteoprotegerin. Interestingly, bone marrow cells isolated from SPARC-null
mice treated with PTH showed a greater propensity for osteoclast differentiation in
comparison to WT cultures and suggested that in the absence of SPARC, PTH has an
enhanced effect on osteoclastogenesis over that of WT cells [82]. Observed increases in
levels of expression of RANKL in PTH treated SPARC-null mice might contribute to
increased osteoclast formation although other cellular mechanisms could also be
important as expression of osteoprotegerin (OPG) was also increased in SPARC-null
cells rendering the RANKL/OPG ratio relatively unchanged [82].
Osteoclasts and macrophages arise from the same precursor monocyte cell lineage
that also derives from bone marrow cell populations. Expression of SPARC by some
monocyte/macrophage cell lines and by monocyte/macrophage populations in tissues has
been reported [90-92]. To date, the expression of SPARC by osteoclasts, either in vitro
or in vivo, has not been reported. As mentioned above, in PTH-treated mice, SPARC
appeared to limit osteoclast formation however the mechanism by which SPARC acts to
influence osteoclast activity is not defined and might involve 1) direct interaction of
extracellular SPARC with osteoclasts, 2) an influence on other cell types that support
osteoclast activity such as immune cells or osteoblasts, or 3) reside in differences in
mineralized ECM assembled in the absence of SPARC.
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The mechanisms by which SPARC influences bone formation, maintenance, and
repair might occur through multiple pathways that include the regulation of procollagen
processing and assembly in the bone matrix, cross-linking, mineralization, and/or
osteoblast/osteoclast differentiation and activity. As each of these processes are tightly
linked to one another, perturbations in one pathway might induce a ripple effect leading
to consequences for other mediators of bone biology. Given the close association of
SPARC with collagen I expression in both mineralized and non-mineralized tissues and
the capacity of SPARC to bind to collagens, strongly suggests that SPARC is critical in
the production and/or deposition of collagen. The recent identification of mutations in
SPARC specifically in the collagen binding pocket region that associate with
osteogenesis imperfecta lend credence to the concept that the collagen-binding function
of SPARC is essential for proper ECM assembly and architecture.

5. Absence of SPARC exacerbates PD
SPARC expression plays aberrant roles in regulating progression of inflammatory
diseases through the ability to attract monocytes and stimulate cell migration mediated by
integrin and CD44 cell surface binding [93, 94]. Extensive research has demonstrated the
involvement of SPARC in cell invasion and metastasis in tumor progression, obesitylinked liver inflammation, cardiac and lung fibrosis-induced inflammation, and diabetes
mellitus [45, 53, 95-97]. Macrophages, activated T cells, and NK cells express SPARC.
Expression of SPARC during inflammatory disease states down regulates antiinflammatory cytokines IL-10 and IL-12 and causes induction of pro-inflammatory
cytokines IL-6, TNF-α, and NF-κB [98, 99]. Pro-inflammatory cytokines activated by
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SPARC enhance macrophage cell migration, survival, and cytokine production [94].
Activation of NF-κB, the “master gene promoter of inflammation” activates the PI3K/Akt
pathway to prevent cell apoptosis during inflammation [100]. SPARC expression by
macrophages enhances endothelial cell extravasation through interaction with VCAM-1
cell surface molecule, which induces actin cytoskeletal rearrangement and intracellular
gaps [101].
The structural integrity of the periodontal ligament is attributed to the high amount of
collagen type I content. SPARC is expressed in all tissues of the periodontium; PDL,
cementum, and alveolar bone [58, 77, 102]. Saliva from patients with PD exhibited
increased levels of SPARC correlating with decreased alveolar bone loss [103, 104].
Various murine models of PD have been utilized to study inflammatory response and
disease progression (summarized in Table 4). Injection of bacterial LPS into the PDL is
one model used to mimic the PD state by inducing an inflammatory response [105].
Previous reports from our laboratory indicated increased loss of alveolar bone volume
fraction and PDL degradation following LPS injections in the absence of SPARC
compared to WT counterparts. Relative bone loss of SPARC-null mandibles following
LPS injections was 2.2 fold higher compared to the bone loss of WT mandibles. As
expected, injection of LPS resulted in robust increases of inflammatory cell infiltrate to
PDL in WT animals. Surprisingly, the percent of inflammatory cells in SPARC-null PDL
following LPS-injection was not only reduced compared to WT LPS-injections but was
even reduced compared to PBS control injections. PDL loss of collagen induced by LPS
was more extensive in the absence of SPARC compared to WT animals.
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Table 4. Experimental Murine Models of PD
Model

Implementation Method

Lipopolysaccharide
(LPS)

•
•

Injection [106]
Oral Gavage [107]

Live bacteria

•
•
•

Injection
Oral Gavage
Strains: Porphyromonas
gingivalis [108],
Campylobacter rectus,
Fusobacterium nucleatum,
Actinobacillus
actinomycetemcomitans[109]
Surgical removal of
periodontal tissues and/or
creation of osseous defects
[110]

Critical size defects

High sucrose diet

Chemical/drug
induction

•

•

•

Disadvantages

Mimics bacterial
toxin produced
during PD
Allows for isolation
of specific pathogens
and characterization
of subsequent disease
outcomes

Lacks bacterial
colonization
phase
Not indicative
of multipathogenic PD
biofilm

Investigation of
region-specific
response to PD
Regeneration of
periodontal tissue
studies

Secondary method used in
conjunction with other primary
method [111-113]

Representative of
natural disease
progression

Trinitrobenzene sulfonic acid
(TNBS) or dextran sulfate
sodium (DSS) treated food
[114]

Quick, easy
induction of strong
inflammatory
response
Developmental
and/or epigenetic
modulators of PD
studies
Highly indicative of
natural disease
progression if used
as sole method

ex vivo Mandibular
Slice Culture

•

Embryonic (E12) tooth germ
slice culture + pathogenic
bacteria [115]

Ligature*

•

Silk or cotton suture tied
around molar(s) to create
periodontal pocket between
gingival tissue and tooth
cementum and allow for
bacterial colonization [116]
Sometimes soaked in LPS/live
bacteria/combined with high
sucrose diet

•

Advantages

Lacks bacterial
colonization
phase
Lacks bacterial
colonization
phase
Not indicative
of progressive
tissue(s)
degeneration
Not standalone method
Potential
induction of
additional
confounding
diseases
Lacks bacterial
colonization
phase
Low
translatability
Low
translatability
Ethical issues
Technically
difficult

Ability to
culture/identify
bacterial population
colonizing ligature

*Model implemented throughout dissertation experiments
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The number of Sharpey’s fibers weaving into alveolar bone was reduced in SPARC-null
PDL following LPS challenge and the width of the same fibers was decreased in SPARCnull PDL with both PBS and LPS injections compared to WT PDL [117]. Increased
alveolar bone loss in SPARC-null mandible was predicted given the role of SPARC in
formation of mineralized matrix. Defects in SPARC-null bone phenotype predispose
mice to accelerated bone loss following LPS challenge. Reductions in SPARC-null PDL
inflammatory cell populations following LPS injections reflect studies that reported an
impaired ability of SPARC-null mice to mount an immune response following LPS
footpad challenge [118]. Loss of PDL collagen content and integrity suggests a critical
role of SPARC to resist collagenase digestion of fibers during an inflammatory disease
state. The reduced number of Sharpey’s fibers following LPS challenge in SPARC-null
PDL is attributed to compensatory mechanisms of an inherently weaker ECM and
alveolar bone composition compared to WT counterparts [117]. PD progression resulting
in an exasperated phenotype in the absence of SPARC is depicted in Figure 5.

6. TG-mediated collagen crosslinking in PDL
Transglutaminases (TGs) are a family of 8 proteins expressed throughout the
body that catalyze extracellular crosslinking [119]. TGs catalyze an irreversible covalent
acyl exchange between a glutamine and a lysine resulting in an isopeptide bond (Fig. 6).
Tissue transglutaminase, TG2, is the most ubiquitously expressed TG family member
[119]. Unlike the 7 other TG family members, TG2 is uniquely capable of acting as a
GTP-ase and a protein disulfide isomerase.
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Figure 5. The absence of SPARC increases PDL collagen degradation and alveolar
bone resorption during PD. 1) The absence of SPARC decreases monocyte
extravasation/macrophage infiltration to site of inflammation 2) Aberrant procollagen
processing and reduced collagen deposition in SPARC-null animals results in a PDL
prone to degradation 3) Decreased mineral density of SPARC-null bones predisposes
alveolar bone to increased resorption during PD.
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Exactly how TG2 is secreted into the extracellular space is unknown since the mRNA
encoding TG2 does not possess a secretion signal. Multiple labs have identified TG2
localization to the ECM in vivo and in vitro, TG2 cross-links in the ECM, and TG2
protein in cell culture media [120, 121].
Human TG2 has four domains: an N-terminal domain capable of binding
fibronectin and a catalytic domain triad composed of cysteine-histidine-aspartic acid
residues and 2 beta-barrels. The catalytic triad of TG2 enables it to bind and use guanine
nucleotides to regulate transamidation unique from other TG family members. TG2 has
been shown to cross-link ECM proteins such as fibronectin and fibrillar collagens.
Studies carried out in cartilage revealed that SPARC could also serve as a substrate for
TG [80]. The catalytic function of TG2 and Factor XIII (plasma TG) is defined as a
protein transamidation reaction that occurs between glutamine and lysine residues
resulting in the formation of a γ-glutamyl-ε−lysyl covalent bond. The crosslinking of
ECM proteins by TG is predicted to promote assembly and/or enhance stabilization of
collagenous and noncollagenous ECMs [119].
TG2 is capable of cross-linking the ECM protein fibronectin during fibril
assembly by acting as a co-receptor for the 42kDa fragment of fibronectin [122]. The
binding of TG2 to fibronectin facilitates association with β1 and β3-integrins. The
association of fibronectin with β-integrins mediated by TG2 promotes cell adhesion and
migration [121]. TG2 also enhances cell spreading and adhesion in fibroblasts in vitro
[121]. TG2 has a TGF-β1 response element located in the promoter region. An increase
in TG2 in fibroblasts resulted in TGF-β1 induction that was NF-κB dependent and a
simultaneous increase of collagen expression in vitro [123].
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Figure 6. Enzymatic action of TG. TG catalyzes the transamidation (cross-linking)
of specific glutamine residues to nearby lysine residues with release of ammonia
resulting in the formation of an isopeptide bone between two proteins.
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Mice lacking TG2 display several abnormalities in their ECM structure and
function. TG2-null mice develop cataracts at an early age compared to WT counterparts
and display gluten sensitivity due to increased cross-linking of glial peptides. These mice
have reports of neurodegeneration, increased melanoma tumor size, and aberrant tissue
remodeling in heart, liver, kidney, and bone [124-126]. TG2-null mice do not develop
interstitial fibrosis and have no alterations in collagen synthesis or deposition compared
to WT mice [125]. Endothelial cells, smooth muscle cells, and fibroblasts constitutively
express TG2 [124]. Multiple studies have implicated TG2 in ECM homeostasis via
transamidation of fibronectin and collagen. Aberrant TG2 activity is associated with
states of fibrosis, wound healing, and altered collagen I cross-linking.
The expression of SPARC was recently shown to influence TG activity in PDL.
As mentioned previously, an absence of SPARC expression results in decreased levels of
collagen I in many connective tissues. In addition to reduced collagen content, collagen
fibrils assembled in the absence of SPARC are smaller and more uniform in diameter
versus those in WT tissues, including PDL. Accordingly, SPARC-null PDL was shown to
have decreased mechanical strength in comparison to WT [66]. SPARC-null PDL also
demonstrated increased TG activity. Specifically, TG activity on collagen I was enhanced
with abrogated SPARC expression. Administration of TG inhibitors to SPARC-null PDL
resulted in increased collagen content and the generation of larger collagen fibers. The
increase in collagen content and the rescued morphology of the collagen fibers was
associated with enhanced mechanical strength of the PDL [66]. SPARC bound to
collagen is predicted to reduce accessibility of TGs to certain glutamine and/or lysine
residues on collagen. Hence, over-modification by TG on collagen might lock collagen

49

fibrils into a smaller diameter preventing further fiber expansion and reducing overall
collagen content and mechanical strength of soft tissues.

7. TG in inflammatory PD
Penetration and damage of the gingival epithelial layer by pathogenic bacteria are
important steps in PD pathogenesis. Alterations between the gingival epithelia and
attachment to the underlying ECM and connective tissues disrupt junctional epithelium
homeostasis and migration during progressive PD. Curro et al. reported increased TG2
mRNA levels along with reductions in TG1 and TG3 mRNA and protein levels in
patients with chronic PD compared to healthy controls [127]. Clinical studies assessing
gingival overgrowth in patients with PD reported significant increases in TG2 expression
histologically in gingival biopsies compared to healthy patients, implicating the role of
TG2 in gingival matrix remodeling [128, 129].
Cui et al. demonstrated in osteoblast cultures that Factor XIII, a circulating TG,
catalyzed the cross-linking of fibronectin from serum (plasma fibronectin; pFn), as
opposed to the EDA-splice variant of fibronectin endogenously expressed by osteoblasts
(cellular Fn; cFn) [119]. Formation of a cross-linked fibronectin matrix derived from pFn
was required for subsequent deposition and assembly of a collagen network. Inhibition of
Factor XIII activity, but not that of TG2, decreased collagen deposition and
mineralization in osteoblast cultures [119]. Hence, cross-linking of pFn by Factor XIII
was predicted to be an essential phase of bone formation that precedes collagen
deposition. Another study revealed enhanced osteoblast cell adhesion properties of two
matricellular proteins mediated by TG2 crosslinks: osteopontin (OPN) and bone

50

sialoprotein (BSP). It was confirmed that both OPN and BSP serve as substrates for TG2
and that their modification by TG2 enhanced the formation of cellular extensions in
osteoblast cell cultures. Similar to Factor XIII, TG2 is found to localize to osteoid,
osteoblasts, and osteocytes and it is hypothesized that these two enzymes work
synergistically to oligomerize substrates [130]. TG might also be an essential factor in
crosslinking of collagen fibers in bone formation. TG2 activity specifically in alveolar
bone during PD has not been reported. Given the implications for TG2 activity during
homeostatic bone growth and development it is likely that TG2 activity axis is altered in
alveolar bone during inflammatory PD.
During PD, macrophages and T lymphocytes produce inflammatory mediators; IL-1,
IL-6, TNF-α, and prostaglandin E2, which induce bone resorption indirectly by
stimulating osteoblasts to produce receptor activator of nuclear factor kappa-B ligand
(RANKL) [131]. RANKL is the ligand receptor for RANK found on the surface
osteoblasts and plays a critical role in bone metabolism by activating osteoclasts and their
subsequent bone resorption. Osteoprotegerin (OPG) is a decoy receptor for RANKL
produced by osteoblasts and fibroblasts. The binding of OPG to RANKL prevents NF-κB
activation and osteoclast differentiation from monocyte precursors [132]. Increased levels
of RANKL mRNA are associated with chronic PD and corresponding increases in
alveolar bone resorption [131]. Cytokines and growth factors secreted during
inflammatory states regulate TG2 expression levels [133]. Concomitant TG2 mRNA upregulation with increased cytokine mRNA levels were reported in cultured human PDL
(HPDL) from PD patients compared to healthy HPDL cells. Human THP-1 cells
differentiated to macrophages exhibited reductions of TG2 activity associated with loss
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of NF-κB activation and reduced RANKL expression. The authors suggest a role of
TG2/NF-κB axis during the inflammatory response by increasing RANKL/OPG mRNA
expression in patients with PD. Inhibition of TG activity in differentiated THP-1 cell
cultures reduced NF-κB and RANKL mRNA levels. Increased TG2 expression in HPDL
cells from patients with PD suggests a role for TG2 in promoting molecular mechanisms
that might contribute to bone resorption in these patients [134]. Currently, there is no
published literature investigating TG activity in PDL as it relates to collagen
assembly/remodeling during PD. One aim of this dissertation work is to explore the
biological role of TG2 specifically in PDL collagen biology during inflammatory PD
progression. The hypotheses to be tested are represented in Figure 7 and 8.
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Figure 7. Proposed Hypothesis. Increased activation of TG and TG-mediated collagen
cross-links in PD results in PDL degradation and smaller collagen fibers, which is further
exacerbated in SPARC-null PDL.
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Figure 8. Cellular Schematic of Proposed Hypothesis. Collagen secreted from WT
PDL fibroblast assembles with the help of chaperone protein SPARC into thick fibrils.
Increased TG expression during inflammatory PD results in partial collagen fiber crosslinking into tighter thinner fibers, while collagen fibers bound by SPARC assemble into
homeostatic thicker fibers resulting in an intermediate fibril formation. In the absence of
SPARC, TG is able to bind increased levels of secreted collagen and cross-link fibers into
tight, thin fibers. The thin fibers formed by TG cross-linking are mechanically weaker,
predisposing the PDL to degradation, and exacerbating the PD phenotype.
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CHAPTER 2: MATERIALS AND METHODS
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Animal Use and Care
SPARC-null mice with global abrogation of SPARC expression and mice carrying the
exon-2 deleted procollagen α1(I) gene were crossed to generate SPARC-null/exon-2
deleted (double-null) mice as previously described [135]. Strategy to generate SPARCnull mice is described in [50] and exon-2 deleted mice in [136]. Single heterozygotes
(KO/het and het/KO) were bred to obtain wild-type controls (wt/wt). Genotyping of all
mice was performed by tail clip DNA extraction followed by qPCR conducted with
specific forward and reverse primers utilizing the GoTaq PCR Core System I (Promega;
Madison, WI). All transgenic lines were maintained on a C57Bl/6/129SV mixed
background. Animals were euthanized via CO2 asphyxiation, followed by cervical
dislocation. Mice were housed in the Ralph H. Johnson Veteran’s Administration (VA)
animal facility and were supplied with a standard diet of hard chow. The described
experiments in this study were conducted under an animal protocol approved by the
Institutional Animal Care and Use Committee (IACUC) of the Medical University of
South Carolina and the Veterans Affairs Medical Center, Charleston, South Carolina,
USA.
Histological Analysis of Collagen Morphology and Collagen Volume Fraction
Mandibles and maxillae from mice were dissected, fixed over night in zinc-formalin, and
decalcified in 0.5M EDTA changed daily for 2 weeks at room temperature. Following
decalcification, jaws were dehydrated in graded ethanol changes, embedded in paraffin,
and sectioned (5-7µm). Sections were mounted on glass slides, rehydrated in xylene
followed by incubation in a series of graded ethanol washes, washed in phosphate
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buffered saline containing 2% tween (PBST) for 10 minutes, then blocked in 3% donkey
serum in PBST.
Picro Sirius Red Staining
Picro Sirius Red (PSR) staining was performed as follows. Slides were stained in iron
hematoxylin for 10 minutes followed by a running water rinse (10 min). The slides were
then stained in PSR (Sigma-Aldrich; St Louis, MO) for 1 hour followed by three 5-min
rinses in 1% acetic acid, dehydrated, and mounted with Clarion mounting medium and
cover slips. Slides were imaged using a 40X objective on an Olympus Bx50WI
microscope (Center Valley, PA) equipped with Infinity 2 Capture software (Electron
Microscope Services; Hatfield, PA). Slides were visualized with polarized light under
which thick collagen fibers appear bright red or red/orange and thin collagen fibers
appear green/yellow in color easily differentiated against a black background. Slides were
also visualized and imaged under bright light, under which all collagen appears red
against a yellow background. Quantitative morphometric analysis of images was
conducted using Visiopharm Integrator System (VIS, version 3.2.9.0) with parameters set
to measure total area of PDL, background area, total collagen area, thick collagen fiber
area (red/orange), and thin collagen fiber area (green/yellow). Bright field PSR images
were quantified for percent total collagen using VIS with parameters set to measure total
area of red-stained collagen in the outlined region of the PDL.
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Herovici Staining
Herovici histological staining was performed utilizing a kit (American MasterTech,
KTHER) and following manufacturing procedure guidelines. Slides were stained with
Weigert’s hematoxylin for 5 min followed by a running water rinse for 45 seconds.
Herovici’s working solution was applied to slides for 2 minutes followed by a 2 minute
immersion in 1% acetic acid, dehydrated for 1 min in absolute alcohol (3 changes),
cleared for 1 min in histoclear (3 changes), and mounted with cytoseal wet mounting
media. Slides were visualized with bright light using a 40X objective on the same scope
utilized for PSR above. Newly formed collagen fibers or thin fibers were stained blue,
homeostatic mature collagen or thick fibers stained red/pink, and nuclei stained black.
Second-Harmonic Generation
Fresh, un-stained, non-fixed, non-decalcified maxillae were dissected from mice, rinsed
in PBS, and soaked in 50% glycerol for 1 hour. Jaw specimens were sliced to obtain a flat
exposed longitudinal slice of PDL tissue using a sledge microtome (SM2400, Leica
Microsystems GmbH, Wetzlar, Germany) with a freezing stage (Model BFS-30,
Physitemp, Clifton, NJ) and optimal cutting temperature (OCT) compound (Sakura
Fineteck 4583, Torrance, CA). Freshly cut specimens were rinsed in PBS to remove
remaining OCT compound and stored in fresh PBS prior to imaging. Imaging was
performed using an Olympus Fluoview 1200 MPA (Olympus, Center Valley, PA) with a
30X oil immersion objective lens (UPLSAPO, 30XSIR; Olympus, Center Valley, PA).
The excitation laser for SHG was at a wavelength of 860 nm, and the signal was collected
in the 420-460 nm range. Image resolution was 1024 x 1024 with a field of view of 423 x
423 µm. For z stack images, slices were taken at a range of 0.2 – 0.5 µm/slice for depths
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up to 100 µm and attenuation compensation was applied to adjust laser power according
to laser depth. Images were analyzed using Fiji for Image J to produce a two-dimensional
discrete frequency Fourier transformation (FFT) along an orthogonal axis to indicate
image frequency function between 0 and 1. DFT accounts for spatial geometric
characteristics of an image. The frequency distribution of the transformed image was
quantified as aspect ratio (AR) using the horizontal and vertical axes of each 2D FFT in
Matlab software. The frequency distribution of the transformed image was analyzed
using Matlab software. Entropy of each image was calculated using Matlab to measure
redundancy of information. Regular repeated patterns result in high entropy values
indicating high level of organization. Low entropy values indicate increased
disorganization of image. The inverse of entropy (1/E) was calculated for each image and
used as the disorganized parameter (DP). Entropy does not take into account spatial
properties, which is why this calculation was combined with FFT for all SHG images.
Three-dimension volume and orthogonal reconstructions of z stack images were creating
using Imaris software.
Mechanical Testing of Mandibular PDL
Dissected mandibles of mice were secured to a base and a 30G wire threaded underneath
the crown of the first molar was secured to an upper clamp elevating with a set rate until
the point of tooth extraction. The force required for extraction was recorded with a load
cell. Detailed set-up schematic and methods of mechanical testing of murine PDL has
been published by our laboratory [66].
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Mechanical Testing of Maxillary PDL
Following ligature-treatment and TG inhibition in vivo, mandible was dissected and
discarded from calvaria. Ligature was removed from 2nd maxillary molar and discarded.
A 40-gauge wire was threaded through the root furcation of the 1st molar on both left and
right sides in the same manner as previously described for mandibular mechanical
testing. Smaller gauge wire was required for maxillary molars versus mandibular molars
to avoid alveolar ridge and/or tooth crown fracture. Additionally, the 1st maxillary molar
was used for testing due to increased fragility of 2nd maxillary molars. Remainder of
murine calvaria, with soft tissue and musculature attached, was rinsed in 70% ethanol and
PBS. Following placement of wires, heads were embedded in plastic resin blocks with
soft palate and molars exposed (Environmental Technology Inc. Fields Landing, CA).
Buccal skin flaps were elevated surrounding soft palate to avoid resin infiltration. Square
resin molds were allowed to polymerize overnight at room temperature. Once fully
polymerized resin blocks were stored at 4°C until next step. Resin blocks were removed
from molds and cut down to fit apparatus clamp size using a dremmel. Resin embedding
and exposure of native tissue at room temperature overnight dehydrated tissues and
increased stiffness. Cut blocks were rehydrated for 6-8 hours in PBS at room
temperature. Wires resistant to oxidation must be used to maintain integrity through this
step. Individual blocks were removed from PBS immediately prior to testing, rinsed in
dH2O, blotted dry, and mounted on testing apparatus. The smaller, 40-gauge, wires
utilized in maxillary testing could only withstand a max force of 5.5 newtons before
failure. Therefore, data is reported as max force instead of mechanical strength for
maxillary testing.
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Other Histology and Immunofluorescence of PDL
Hematoxylin & Eosin
Histologically prepared mandibular and maxillary sections were stained with
hematoxylin and eosin (H&E) and visualized under bright light. Rests of Malassez were
identified as multi-cellular clusters of epithelial cells within the PDL situated along the
tooth

cementum

border.

Results

of

H&E

staining

were

confirmed

by

immunofluorescence using a monoclonal antibody generated against mouse cytokeratin
(Sigma-Aldrich, St. Louis MO, Fig. 6E-H). A 1:200 primary antibody concentration with
overnight incubation at 4°C was followed by a 1-hour incubation with a fluorescein
conjugated anti-mouse secondary antibody at a 1:200 concentration (AlexaFluor 488).
Secondary-only sections were used as negative controls. Prolong anti-fade containing
DAPI (Molecular Probes, Eugene, OR) was used to mount cover slips and sections were
viewed on an Olympus fluorescent microscope.
Immunofluorescence
Immunohistochemical staining was performed according to the following protocol.
Following deparafinization and dehydration, slides were incubated in 1% hydrogen
peroxide in methanol for 30 min to quench endogenous peroxidase activity. Nonspecific
binding was blocked by incubating slides in 2% donkey serum in PBS for 30 min at room
temperature. Slides were incubating in anti-Ki67 (abcam 15580) in a 1:500 concentration
at 4°C overnight. The slides were sequentially detected with avidin-biotin-peroxidase
(Thermo Scientific 32020), using 3,3’-diaminobenzidine, tetrahydrochloride (DAB,
Thermo Scientific 34065) as a substrate. Nuclei were counterstained with 15% Ehrlich’s
hematoxylin. Normal donkey serum was used in place of the primary antibody as a
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negative control. Images were quantified for the number of individual rests, for % area
occupied by the rests within the PDL, and for the number of proliferating (Ki67+) cells.
Immunohistochemistry
Immunohistochemical multiple antigen labeling to confirm fibroblast cell type was
performed by the following protocol. Slides were incubated in anti-Ki67 (abcam 15580)
in a 1:500 concentration at 4°C overnight and sequentially detected with avidin-biotinperoxidase (ABC) and DAB substrate. Following PBST wash and rodent block, slides
were incubated for 2 hours in mouse monoclonal anti-vimentin (abcam 8978, RV202) in
a 1:50 concentration at room temperature. Slides were incubated with mouse on mouse
HRP polymer (Thermo Scientific TL015QHDM) for 1 hour at room temperature,
washed, developed with ImmPACT VIP substrate (Vector Laboratories SK-4605) for 10
minutes, dehydrated, cleared, and mounted using cytoseal wet mounting media. No
counterstain was applied.
Micro-computed Tomography and Bone Volume Fraction Analysis
Mandibles and maxillae were harvested from mice at experimental age points. Excess
soft tissue and surrounding musculature was removed. Non-demineralized jaws were
washed in PBS and fixed overnight in zinc-formalin at room temperature. Following
fixation, jaws were rinsed 3 times in dH2O and transferred to 70% EtOH until scanned.
Specimens were scanning by a Scanco Medical µCT 40 system (Scanco USA, Wayne,
PA, USA) and analyzed with GE microview software (version viz. +2.0 build 0029) for
quantification of bone volume fraction (BV/TV). Each scan was reconstructed at a mesh
size of 18 x 18 x 18 µm to create a 3D digitized image for each specimen. The images
were then rotated into a standard orientation and a threshold at 1621 was used to
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distinguish between mineralized and non-mineralized tissue. The region of interest (ROI)
for the bone volume/tissue volume analysis was based on 3 easily identifiable anatomical
landmarks of each jaw: 1. Mesial CEJ of 1st molar to distal CEJ of 3rd molar with jaw
oriented in mid-sagittal view, 2. Tips of crown cusps, and 3. Apical portion of anterior 3rd
molar root (Fig. 9). Buccal:palatal aspects of ROI box are resized according to landmarks
and 0.9mm are added to the ROI on the Z-axis. BV/TV was then calculated using the GE
MicroView software bone analysis module. All µCT scans were blindly assessed and
quantified by an independent laboratory technician.
Ligature Model of PD
Mice at a minimum of 6 weeks of age were individually anesthetized in a 5.0%
isofluorine chamber supplied 0.6 L/min O2 at 14.7 PSI. Anesthetized mice were
transferred to a heated operating platform set to 37°C and 630 mA (KE OP-T, Vestavia
Scientific, Birmingham, AL) and ventilated by nose comb supplied with 2.5% isofluorine
and 0.6 L/min O2 at 14.7 PSI (Mouse MiniVent, type 845, model D-79323, Hugosachs
Electronik, Germany). Mandible, maxilla, and cheeks were retracted and a 0.5 metric silk
ligature (Covidien, VS-809, D3C0135X, Mansfield, MA, USA) was placed around the
left maxillary second molar, following a previously described protocol [116], using a
Zeiss dissecting microscope (OPMI 1-H, 93534) (Fig. 10). Right maxillary molars were
left untreated to serve as internal controls. Ligatures were left in place for 5- and 14-day
time points and checked to ensure secure placement every other day. On day of sacrifice,
animals were euthanized by CO2 asphyxiation followed by cervical dislocation. Silk
ligatures were removed from maxillae and discarded prior to further experimentation
(except in the case of organ culture).
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Figure 9. ROI Anatomical Landmarks Used for Micro-Computed Tomography
Analysis of Bone Volume Fraction.
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Figure 10. Set-up of left maxillary 2nd molar ligature placement.
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F4/80+ Macrophage Immunohistochemistry
Slides were prepared from sectioned ligature-treated and control jaws as described above
and incubated in anti-F4/80 (LifeTechnologies MF48000, Frederick, MD, USA) in a
1:200 concentration overnight at 4°C followed by PBST washes and incubation in
secondary antibody at 1:200 concentration for 1 hour at room temperature.
Immunoreactivity was detected with ABC and DAB substrate. Secondary-only sections
were used as controls.
Peripheral Blood Lineage Tracing
Mononuclear Cell Preparation
To assess potential inherent differences in hematopoietic cell lineages in WT versus
SPARC-null mice a peripheral blood lineage panel was performed. Peripheral blood
mononuclear cells were prepared using fresh whole blood (80-100µl) collected from
mouse (age 3-4 months, n=3 males and 3 females/genotype) by tail clip. Heparin was
added to each sample to prevent blood coagulation. Each sample was divided into 3 wells
and stained with 3 primary antibodies: GR1/Mac1, CD4/CD8, and NK/B220 at a 10ug/ml
concentration. One sample was divided into 6 wells and additionally stained with
allophycocyanin (APC) and phycoerythrin (PE) for isotype controls and one left
unstained for a “cells-only” control. All antibodies were purchased from BD Biosciences.
Cells were incubated on ice for 20 minutes. Pharmlyse was added to each sample and
incubated on ice for additional 15 minutes. Following lysing, samples were washed in
0.1% BSA/PBS, spun down at 200xg for 5 minutes, decanted, and resuspended in PBS in
preparation for FACS analysis.
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Flow Cytometric Analysis
Freshly prepared PB samples were analyzed by a FACSCalibur flow cytometer (Becton
Dickinson, San Jose, CA, USA). Live/dead gating was not compensated for with
propedium iodine (PI) since fresh PB protocol is quick, lacks manipulations, and thus is
expected to have very low to no dead cells. Gates were set using isotype controls and data
was collected for the first 10,000 events.
TRAP Staining
For enumeration of multi-nucleated osteoclasts, tartrate-resistant acid phosphatase
(TRAP) staining was performed on 5-day and 14-day ligature and control sections from
WT and SPARC-null mice by means of a Leukocyte Acid Phosphatase kit (Sigma, St.
Louis, MO, USA). Active osteoclasts were defined as multinucleated (≥3) TRAP-positive
cells in contact with the bone surface. Images were captured on the Olympus Bx50WI
microscope at 4x, 20x, and 40x objectives. Enumeration of osteoclasts was performed
using the VIS software.
Alkaline Phosphatase (ALP) Staining
To characterize and quantify osteoblast cell population response to ligature-induced
inflammation, ALP activity was detected histologically. Following deparaffinization,
sectioned slides from WT and SPARC-null control and ligature specimens were
incubated for 1 min in microwaved sodium citrate buffer (pH 6.0) and allowed to cool to
room temperature in ddH2O. Endogenous peroxidases were blocked in a 3% hydrogen
peroxide + methanol solution for 10 minutes. Sections were washed 3x in PBS followed
by a 10 min block in goat serum. Slides were incubated in primary anti-alkaline
phosphatase rabbit monoclonal antibody (ab108337) in a 1:250 concentration for 1 hour
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at room temperature. Following PBS washes, slides were incubated in secondary
antibody (ab6721) in a 1:250 concentration for 1 hour, washed, detected with DAB
substrate, and counterstained with Harris hematoxylin (diluted 1:10 in ddH2O) for 30
seconds then coverslips were mounted with Permount mounting medium. Images were
captured on the Olympus microscope at 20x and 40x objectives and ALP reactivity was
quantified utilizing VIS software.
TG Expression and Epitope Staining
To assess differences in TG2 expression levels and cross-linking activity through the
formation of N-ε-γ-glutamyl lysine bonds immunohistochemistry was performed on WT
and SPARC-null maxillary sections following 5-day ligature treatment and corresponding
controls. Sections were prepared and processed through the IHC DAB protocol described
above. WT and SPARC-null slides with and without 5-day ligature treatment were
incubated in polyclonal anti-TG2 primary antibody (covalab, pab0024-P, Villeurbanne,
France) for TG2 expression and in a monoclonal anti-N-(L-glutamyl)-L-lysine isopeptide
primary antibody (covalab, mab0009-P, Villeurbanne, France) for TG2 cross-linking
activity at a concentration of 1:200 at 4°C overnight and corresponding secondary
antibodies (anti-rabbit and anti-mouse, respectively) at a concentration of 1:200 for 1
hour at room temperature. Secondary only sections were used as controls. Slides were
mounted with glass coverlips using Permount.
TG Inhibition
In vivo Inhibition of TG with Biotinylated Cadaverine Injections
Twenty-two 2-3-month old WT C57Bl/6J male mice were used. Ten mice were used for
protein analysis of biotinylated cadaverine PDL incorporation. Each mouse was
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anesthetized and the left 2nd maxillary molar was ligated as described above. Following
ligation, each mouse was injected with either 2 µL of biotinylated cadaverine (BC)
(Sigma-Aldirch, A5348) (2 mM in DMSO) (n = 5) or 2 µL of DMSO vehicle (Invitrogen
(n = 5) in the PDL around the 2nd maxillary molar on both the left (ligated) and the right
(non-ligated control) side. Mice received injections daily for 4 days. A second set of mice
(n = 6: BC n = 3, DMSO n = 3)) were ligated and injected for second harmonic
generation imaging. A third set of mice (n = 6: BC n = 3, DMSO n = 3) were ligated and
injected for immunohistochemistry. At day four, 3 hours following same-day injection,
the mice were harvested and jaws were collected for organ culture described below.
In vitro Organ Culture
Maxillae were removed from 2-3 month old WT mice and dissected free of muscle and
loose tissue. Jaws from a single mouse were placed in one well of a 24-well plate with 1
mL of growth media (DMEM 10% FCS, 0.2% primocin, 50µg/mL ascorabate). Growth
media was supplemented with BC (2 µM) or equal volumes of vehicle control (DMSO)
as warranted by experimental design. Jaws were then incubated at 37°C, with 5% CO2 for
24 hours prior to molar extraction. Molars from a single mouse (3 left molars, 3 right
molars) were separated and placed in 100 µL of 2.5% SDS in dH2O, supplemented with
protease inhibitors (Roche, Indiannapolis, IN, USA) or were freshly harvested for SHG
imaging or decalcified as described previously and processed for immunohistochemistry.
Extracted molars receiving same treatment were pooled into one sample. Four treatment
groups from n = 10 WT mice were as follows: n = 30 left molars DMSO + ligature, 30
right molars DMSO no ligature control, 30 left molars BC + ligature, 30 right molars BC
no ligature control. Teeth were stored at -80°C overnight and then tumbled at 4°C for 4
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hours to extract PDL protein. Teeth extracted in SDS buffer were boiled, vortexed, and
then boiled for an additional 5 min. After boiling, these samples were centrifuge at
10,000g for 10 min, and the supernatants used for immunoblot analysis (Fig. 11).
Immunoblotting
Equal amounts of protein were separated by SDS-PAGE analysis followed by staining
with Coomassie brilliant blue to confirm equal loading or transferred to nitrocellulose
membranes. Membranes were blocked in 3% bovine serum albumin in Tris-buffered
saline with 0.2% Tween (TBST) for 1 hour at room temperature. Membranes were then
incubated with primary antibodies, anti-collagen α1(I) (1:10,000 dilution; MD
Biosciences, St. Paul, MN, USA), avidin-horseradish peroxidase (HRP) (to detect BC)
(Vector Laboratories, Burlingame, CA, USA), anti-TG2 (1:10,000 dilution; Covalab,
pab0024-P, Villeurbanne, France), and anti-SPARC (1:5,000 dilution, R&D Systems,
942-SP, Minneapolis, MN, USA) followed by appropriate secondary antibodies (Vector
Laboratories) and detection with chemiluminescence reagent (Pierce, Grand Island, NY,
USA). The intensity of bands generated from TG modification by labeled donor substrate
was quantified with NIH Image J software.
Human PDL Fibroblast Cell Culture
Extracted teeth were collected (in DMEM/20%FBS/2%PS/250µg/ml gentamicin
sulfate/2.5 µg/ml amphotericin B) from MUSC Department of Oral and Maxillofacial
Surgery in collaboration with Dr. Meenal Mehrotra in the Department of Pathology and
Laboratory Medicine. Routine wisdom teeth extractions were used as healthy controls.
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Figure 11. Method to inhibit TG in vivo and in vitro.
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Teeth extracted from patients suffering from chronic inflammatory PD were designated
to the diseased group. Teeth were transported on ice and rinsed thoroughly in PBS. Tooth
roots were scraped with a scalpel to collect PDL tissue, which was pooled into 1 tube and
washed 2-3 times with PBS. Tissue was digested in 750 µL solution of dispase (4mg/ml)
and collagenase (3mg/ml) in PBS for 1-2 hours at 37°C, vortexing in between. Following
digestion, 2 mL of media was added to the tube and vortexed. The solution was filtered
through 70uM filter and collected in a new tube. PDL tissue was washed once with
media, filtered, and added to the new tube. Mixture was centrifuged and the cell pellet
washed once with media. Cells were then plated in culture medium containing ascorbic
acid (AA) and L-glutamine (L-glut) for 2-3 weeks. Cells and media were collected at
passage 5 for immunoblotting with antibodies listed above.
Statistical Analysis
The number of experimental animals used was based on previous results. A paired
student’s t-test was used to calculate p-values within genotypes. For comparisons
between genotypes with one condition a student’s t-test was used to calculate p-values.
For comparisons between genotypes with more than one condition, ANOVA analysis
followed by Tukey test was used to calculate p-values. For all analyses, p < 0.05 was
considered statistically significant.
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CHAPTER 3: RESULTS
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Section 1. SPARC and the N-propeptide of collagen I influence fibroblast
proliferation and collagen assembly in the PDL.
The function of the N-propeptide of Collagen I is undefined. Results from
Bornstein et al. and Card et al. suggested no phenotype in transgenic mice with an Npropeptide deletion and only observed a phenotype in dermal tissues when the Npropeptide deletion was combined with an absence of SPARC [135, 136]. Herein, we aim
to examine the N-propeptide phenotype, and potential functional role, in the PDL.
Decreases in Collagen Content and Fiber Size of SPARC-null/exon-2 deleted PDL
Previously, decreases in collagen content and fiber thickness were reported in
SPARC-null (ko/wt) PDL compared to WT [58]. PSR-stained images were used to
evaluate collagen content and fiber thickness in PDL of ko/ko, ko/wt, and exon-2 deleted
mice (wt/ko) in comparison to wt/wt. Representative images from 1-month old mice are
shown in Figure 12, A-D. Quantification of PSR images viewed under polarized light
demonstrated reduced amounts of total collagen in SPARC-null (ko/wt), exon 2-deleted
(wt/ko) and double-null (ko/ko) mice at 1- and 3-months of age versus WT (wt/wt) (Fig.
11E). The most dramatic decrease in total collagen in double-null mice was detected at 3
months at which time the double-null PDL had significantly less collagen than either
single transgenic. Whereas exon-2 deleted (wt/ko) mice exhibited reductions in total
collagen at 1 and 3 months, at 12 months of age, the PDL of these mice exhibited
increased amounts of total collagen versus WT mice and indicated an age-dependent
effect in the N-propeptide deleted mice (Fig. 12E).
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Figure 12. Total collagen I content is reduced in double-null PDL. Representative
Picro Sirius Red (PSR) stained images of 1-month PDL from wt/wt (A), wt/ko (B), ko/wt
(C), and ko/ko (D) viewed under polarized light. Images taken at 40X magnification. n=5
mice/genotype, 5 sections/mouse. Bar in A=25 µm and applies to all panels. E. Total
collagen I content of PDL at 1-, 3-, and 12-month age points. *p<0.05 compared to
wt/wt. #p<0.05 compared to ko/ko.
Figure 13. Percent total collagen I content
is reduced in double-null PDL at all age
points. Representative bright field images of
Picro Sirius Red stained 1-month PDL from
wt/wt (A), wt/ko (B), ko/wt (C), ko/ko (D).
Images taken at 40X magnification. Images
are oriented with alveolar bone on bottom,
PDL center, and tooth cementum on top. n=5
mice, 5 sections/mouse. Bar in A=25 µm and
applies

to

all

panels.

Method

of

quantification is shown in E followed by
graphical representation in F of PDL at 1-, 3, and 12-month age points. *p<0.05 vs.
wt/wt. #<0.05 vs. ko/ko.
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Likewise, double-null mice at 12 months of age demonstrated collagen content similar to
that of SPARC-null mice suggesting the activity of the N-propeptide to influence
collagen content was decreased at 12 months of age. Results reflecting percent total PDL
collagen content were also assessed using bright field PSR images and quantification
(Fig. 13).
Morphological analysis of PSR-stained images revealed thinner collagen fibers in
each of the transgenic mice at 1- and 3-months of age versus that in WT PDL (Fig. 14).
At 3 months of age, double-null PDL had significantly less thick collagen fiber content
than either of the single transgenics. At 12 months of age, mice lacking exon 2
demonstrated significantly more thick fiber content in the PDL than WT, SPARC-null, or
double null PDL. The persistence of thin fiber content in SPARC-null PDL was also
reflected in the thin fiber content of double null mice at 12 months of age (Fig. 14).
Hence, similar to collagen content, effects of the N-propeptide in regulating collagen
fiber assembly appear to shift with age whereas the lack of SPARC in double-null mice
appears to dominate collagen fiber morphology at 12 months.
Herovici stained 1- and 12-month PDL sections reveal distinct staining patterns of
collagen fibers in each genotype (Fig. 15). Thicker collagen fibers stain red/pink with
Herovici stain whereas thinner fibers appear blue. At 1 month of age, wt/wt PDL stained
with Herovici’s stain showed the presence of both red and blue fibers (Fig. 15A) whereas
in wt/wt PDL at 12 months of age, red fibers appeared to dominate the sections (Fig.
15E), suggesting maturation of collagen fibers with age. Interestingly, an apparent
increase in red fibers in 1-month wt/ko over that of wt/wt PDL was noted (Fig. 15B vs.
A).
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Figure 14. A consistent reduction in collagen I fiber size observed in double-null
PDL from 1-month to 12-months of age. Collagen fiber morphology represented by
thin vs. thick fibers quantified from PSR histology for three age points. n=5
mice/genotype, 5 sections/mouse. *p<0.05 compared to wt/wt counterparts, #p<0.05
compared to single transgenics.
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Figure 15. Collagen fiber morphology altered in double-null PDL at 1- and 12month age points. Representative images of Herovici stained PDL from wt/wt (A&E),
wt/ko (B&F), ko/wt (C&G), and ko/ko (D&H) shown at 1- and 12-months of age
respectively. Red/pink stain indicates thicker collagen fibers; blue stain indicates thinner
collagen fibers, nuclei stain black. Images captured at 40X and oriented with alveolar
bone on bottom, PDL center, and tooth cementum on top. Bar in A&E=25 µm and
applies to all panels. n=3 mice/genotype, 5 section/mouse.
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Overall apparent decreases in stain intensity are visible in ko/ko 1 month PDL
indicative of overall reduction in collagen content (Fig. 15D). At 12 months of age (Fig.
15E-H), differences between transgenic mice were not as significant as the 1-month time
point. Interestingly, the predominant red staining of collagen fibers evident at 1 month in
wt/ko PDL appears to be reduced at 12 months of age (Fig. 15F). Double-transgenic
ko/ko 12 month PDL displays loss of red-stained fibers when compared to single
transgenics; resulting in a PDL consisting primarily of blue-stained collagen fibers (Fig.
15H).
Mechanical Strength of PDL
Reductions in total collagen content and fiber morphology have been reported to
correlate with decreases in mechanical strength of SPARC-null PDL [66]. Measurements
of the force required to extract teeth from each genotype at 1 month of age are shown in
Fig 16. Consistent with previous reports, the force required to extract SPARC-null
(ko/wt) teeth was significantly decreased compared to WT and exon-2 deleted (wt/ko)
teeth [137]. Double-null (ko/ko) PDL exhibited further decreases in mechanical strength
compared to both WT and SPARC-null (ko/wt) PDL (Fig. 16). Unexpectedly, exon-2
deleted (wt/ko) teeth required greater forces to extract teeth compared to WT (wt/wt)
despite reduced amounts of total collagen and thick collagen at 1 month of age as
measured by PSR stain (Fig. 12&14).
Increases in Fibroblast Proliferation in SPARC-null/exon-2 deleted PDL
Fibroblasts are the primary cell type that synthesize and secrete collagen in the
PDL [138].
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Figure 16. Mechanical force of tooth extraction varies among transgenic PDL.
Quantification of n=4 mice, 2 replicates/mouse. *p<0.05 compared to wt/wt, #p<0.05
compared to single transgenics.
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Figure 17. Ki67 expression is increased in single- and double-transgenic murine
PDL. Representative images of Ki67 immunohistochemistry localized in sections of PDL
from wt/wt (A), wt/ko (B), ko/wt (C), and ko/ko (D) 1-month mice. All images are
oriented with tooth on top, PDL center, and alveolar bone on bottom; 40X magnification.
Bar in A=100 µm and applies to all panels. (E) Quantification of n=5 mice/genotype, 5
sections/mouse. *p<0.05 compared to wt/wt, #p<0.05 compared to single transgenics.
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To detect whether transgenic mice exhibited differences in fibroblast proliferation
immunohistochemistry, using Ki67 as a marker of proliferating cells, was performed.
Representative images from each genotype are shown in Fig. 17A-D. Quantification of
Ki67 positive cells demonstrated a marked increase in proliferating cells in SPARC-null
(ko/wt) and exon-2 deleted (wt/ko) PDL over that of WT PDL at 1 month (Fig. 17E).
Increases in Ki67 positive cells were observed in 1-month double-null PDL compared to
single transgenics or WT PDL. Double antigen labeling using Ki67 and
vimentin supported that the predominant cell type displaying increases in proliferating
cells were PDL fibroblasts (Fig. 18).
Increases in Epithelial Rests of Malassez in SPARC-null/exon-2 deleted PDL
H&E staining of transgenic PDL revealed an increase in the number of rests of
Malassez in SPARC-null/exon-2 deleted (ko/ko) versus WT (Fig. 19A-D) as well as
increased size of ERMs (determined by %PDL occupied by ERMs) in 1-month SPARCnull/exon 2-deleted PDL (ko/ko) compared to single transgenics and WT (Fig. 19J).
Cytokeratin is present in the periodontium during tooth and PDL development in the
enamel organ, junctional epithelium, and in rests of Malassez [139]. In adults, the only
remnants of cytokeratin expression in the PDL are found in the rests of Malassez.
Immunofluorescence using a pan-cytokeratin antibody confirmed significant increases in
number of ERMs/PDL section (Fig. 19E-H). At 12 months of age, double-null PDL
displays expansion of ERMs and PDL area occupied by these rests in comparison to less
dramatic increases found in WT and SPARC-null PDL (Fig. 19I, J). Interestingly, the
number and area of the ERMs decreased in PDL of exon-2 deleted mice at 12 months in
comparison to both 1-month values and WT values at 12 months (Fig. 19I).
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Figure 18. Ki67 and vimentin double antigen labeling supports increases in
fibroblast proliferation in transgenic PDL. Representative images of Ki67 and
vimentin immunohistochemistry localized in sections of PDL from wt/wt (A), wt/ko (B),
ko/wt (C), ko/ko (D) 1-month old mice. Ki67+ cells stained brown and vimentin+ cells
stained purple. All images are oriented with alveolar bone on bottom, PDL center, and
tooth cementum on top. Images taken at 40X magnification. Bar in A=50 µm and applies
to all panels. Black arrows indicate representative cells positive for both Ki67 and
vimentin. White arrows indicate representative Ki67 positive, vimentin negative cells.
Black arrowheads indicate representative Ki67 negative, vimentin positive cells.
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Figure 19. Number and size of epithelial rests of Malassez (ERMs) varies in murine
periodontal ligament (PDL). Representative sections from 1 month wt/wt (A), wt/ko
(B), ko/wt (C), and ko/ko (D) PDL stained with H&E. Black arrows indicate multicellular ERMs. Bar in A=25 µm and applies to all panels. Representative images from 1
month PDL stained for cytokeratin immunoreactivity (green); wt/wt (E), wt/ko (F), ko/wt
(G), ko/ko (H). Nuclei stained blue (DAPI). White arrows indicate multi-cellular rests of
Malassez expressing cytokeratin. Images are representative of n=3 mice/genotype. I.
Quantification of average number of rests present in sampled PDL. J. Percent of PDL
area occupied by rests. n = 5. *p<0.05 compared to wt/wt, #p<0.05 compared to single
transgenics.
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Alterations of Alveolar Bone Volume Fraction in SPARC-null/exon-2 deleted Mandible
To determine whether transgenic mice demonstrated differences in bone density,
mandibular bone volume fraction (BV/TV) were measured by microcomputed
tomography (µCT) analysis at 1-month (Fig. 20). Single-transgenic exon-2 deleted
(wt/ko) mice displayed decreased levels of alveolar BV/TV when compared to WT
counterparts. SPARC-null (ko/wt) mice had the highest BVF compared to all genotypes.
The loss of the N-propeptide in the absence of SPARC (ko/ko) resulted in increased
alveolar BV/TV compared to both single-transgenic and WT mice (Fig. 20).

Section 2. Ligature-induced PD induces greater loss of periodontal tissues and alters
monocyte-derived cellular response in SPARC-null mice.
Previous reports from our laboratory utilizing an LPS-induced model of PD
reported reduced inflammatory infiltrate present in SPARC-null PDL compared to WT
PDL. SPARC-null mice also displayed greater bone loss following LPS challenge
compared to WT mice, and marked deficits in PDL collagen content and morphology
versus WT PDL [117]. These results suggested that inherent differences in ECM
composition are critical for determining PD outcomes. LPS injections are frequently
critiqued due to the lack of bacterial colonization phase and natural PD progression of
this model. To extend the results of our previous study we employed a ligature-induced
model of PD to circumvent the shortcomings of the LPS model. We first aim to validate
the clinical relevance of the ligature model and to further investigate alterations to PD
progression and ECM remodeling in the absence of SPARC.
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Figure 20. Loss of SPARC or N-propeptide deletion have opposite effects on murine
alveolar bone volume fraction (BV/TV). Representative µCT images of 1-month mouse
mandibles (left) from wt/wt (A), wt/ko (B), ko/wt (C), and ko/ko (D). E) Quantification
of mandibular BV/TV of transgenic mice indicates significant differences in alveolar
bone volume fraction of both single transgenics and double transgenics when compared
to wt/wt. n = 8 for each genotype and samples were equally distributed by gender.
*p < 0.01 compared to wt/wt.
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Ligature Model Reduces Alveolar Bone Volume Fraction in Murine Maxillae
To best represent natural disease pathogenesis we adopted the ligature-induced
model of PD, initially described by the laboratory of George Hajishengallis [116], as a
clinically-relevant model (Fig. 21A). Maxillary alveolar bone volume/total volume
(BV/TV) was assessed by microcomputed tomography (µCT) analysis at 5- and 14-day
time points following ligature placement in SPARC-null and WT mice. Significant
(p<0.05) decreases in alveolar BV/TV in both WT and SPARC-null ligated maxillae
were used as a clinical hallmark of PD. Significant reductions in alveolar BV/TB in both
WT and SPARC-null with ligature at the 5-day time point (Fig. 21C). By 14 days, WT
mice recovered bone volume to levels not significantly different from baseline, whereas
SPARC-null maxillae had persistent decreases in BV/TV (Fig. 21D).
Increased Monocyte-Derived Cell Populations Following Ligature are Reduced in
SPARC-null PDL
Immunohistochemistry of monocyte-derived F4/80 positive macrophage cell
populations revealed robust increases following ligature in WT PDL compared to control
non-ligated PDL (Fig. 22; indicated by arrows). The presence of SPARC-null F4/80+ cell
populations also increased in PDL following ligature-induced inflammation, but to a
lesser extent when compared to WT ligature cell populations (Fig. 22).
Ligature Increases Osteoclast Activity and Alters Distribution in PDL
Since both macrophages and osteoclasts derive from the same monocyte precursor
cell, tartrate-resistant acid phosphatase (TRAP) staining was conducted on WT and
SPARC-null PDL, following 5-day (Fig. 23A & B) and 14-day ligature, to indicate
multinucleated bone-lining osteoclast cell populations.
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Figure 21. Ligature model significantly reduces alveolar bone volume fraction. A)
Ligature in vivo model. B) Representative µCT images of ligature-induced alveolar bone
loss around second maxillary molar (blue arrows). C) Bone volume/tissue volume
(BV/TV) quantification following 5-day and D) 14-day ligature. n=5. *p<0.05.
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Figure 22. Ligature increases F4/80+ cell populations in WT and SPARC-null PDL.
Representative images of F4/80 immunohistochemistry of WT and SPARC-null PDL +/following 5-day ligature. Blue arrows indicate characteristic F4/80+ cells. Images
captured at 20X magnification. n=2.
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Quantification of TRAP+ cell populations revealed significant increases following
ligature of WT PDL at both 5- and 14-day time points (Fig 23C & D). Recapitulating the
F4/80 IHC (Fig. 22), SPARC-null PDL also exhibited increased TRAP+ staining
following ligature at 5-day time point versus control but the response was muted
compared to WT PDL at day 5 (Fig. 23C). Interestingly, SPARC-null TRAP+ staining
was not significantly different following 14-day ligature compared to control (Fig. 23D).
Distribution of TRAP+ cells increased in both WT and SPARC-null PDL, decreased in
WT bone lacunae, and decreased at the SPARC-null PDL:bone interface at 5-days (Fig
23D). Following 14-day ligature WT TRAP+ increased at PDL:bone interface and
decreased in alveolar bone lacunae; no significant changes detected in SPARC-null
TRAP+ distribution at this time point (Fig. 23E & F).
Ligature-Induced Changes in Monocyte Cell Populations not Attributed to Inherent
Differences in Hematopoietic Cell Lineages of WT and SPARC-null Mice
To assess potential inherent differences in hematopoietic lineages that could
contribute to differences in macrophage and/or osteoclast cell populations, flow
cytometric analysis was conducted on peripheral blood of WT (Fig. 24C) and SPARCnull mice (Fig. 24D). Gender differences between male and female mice of both
genotypes were assessed. Experiment was replicated in triplicate to confirm results. We
report no inherent differences in the circulating hematopoietic cell lineages between WT
and SPARC-null mice (male and female). These results indicate that differences observed
between WT and SPARC-null inflammatory infiltrate in PDL following PD are not due
to genetic variations in monocyte precursor cells.
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Figure 23. Ligature aberrantly affects TRAP+ cell populations in WT and SPARCnull PDL at 5- and 14-day time points. A) TRAP staining in WT and SPARC-null PDL
5-day ligature, 4X magnification, scale bar = 100µm and B) 40X magnification, scale bar
= 25µm. C) & D) Average number of TRAP+ cells at 5- and 14-day time points,
respectively. E) TRAP+ cell distribution at 5-day, p*<0.05 vs. control, #p<0.05 vs. WT,
and F) 14-day time points.*p<0.01 vs. control. SPARC-null displayed no significant
differences compared to control or WT. n=3, 5sections/mouse for all quantification.
91

Figure 24. Hematopoetic cell lineages do not differ between WT and SPARC-null
mice. A) Representative example of gating and B) isotype controls used for flow
cytometric analysis. C) Representative flow cytometric analysis showing percent of WT
and D) SPARC-null peripheral blood cells positive for CD8 and CD4 (top right panel),
cell populations positive for Mac1 and Gr1 (bottom left panel) and those positive for
B220 and NK (bottom right panel).

92

Osteoblast Populations Unchanged in SPARC-null PDL Following Ligature
Changes to osteoclast cell populations are sometimes attributed to alterations in
the osteoclast:osteoblast coupling events that take place during bone homeostasis and
turnover. Alkaline phosphatase (ALP), a marker of osteoblast activity, was used to
conduct immunohistochemistry on WT and SPARC-null PDL following 5-day ligature
treatment. WT control PDL displayed an unexpected high level of ALP expression,
which decreased following 5-day ligature (Fig. 25). SPARC-null PDL revealed decreased
ALP expression when compared to WT, which did not significantly change following 5day ligature treatment (Fig. 25B).
SPARC-null PDL Collagen Content is Reduced in Ligature Model
Picro Sirius red (PSR) histological staining of WT and SPARC-null PDL (Fig.
26A) with and without ligature (5- and 14-day time points) visualized under polarized
light was conducted and quantified by morphometric analysis. Total collagen I content of
both WT and SPARC-null PDL had significant reductions following 5-day ligature
compared to controls (Fig. 26B). SPARC-null control PDL demonstrated significantly
less total collagen content compared to WT control, reflective of our previous reports
(Fig. 26B,C). Following trends observed in bone (Fig. 26D), WT PDL collagen content
recovered to non-significant levels with 14-day ligature whereas SPARC-null PDL did
not (Fig. 26C). Thin collagen fibers of WT PDL, differentiated by green/orange
birefringence increased following ligature at both time points (Fig. 26E, F). High levels
of thin collagen fibers in SPARC-null PDL remained constant following ligature at both
time points (Fig. 26E, F).
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Figure 25. Alkaline phosphatase expression is unchanged in the absence of SPARC.
A) Representative IHC images of WT (+/+) and SPARC-null (-/-) control and 5-day
ligature treated PDL following staining for alkaline phosphatase expression (brown
precipitate). Scale bar in top left panel = 25µm and applies to all panels. B)
Quantification of ALP expression. n=5 mice, 5 sections/mouse. #p<0.05 vs. control.
*p<0.05 vs. WT.
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Figure 26. SPARC-null PDL collagen content and fiber diameter are further
reduced in ligature model compared to WT. A) Representative Picro Sirius Red (PSR)
images of WT and SPARC-null PDL following 5-day ligature. B) Quantification of total
collagen I content of PDL following 5-day and C) 14-day ligature. D) Representative
images of Herovici-stained WT and SPARC-null PDL following 5-day ligature. E)
Quantification of thin collagen fibers (green/yellow) from PSR images following 5-day
and F) 14-day ligature. Scale bar in A and D = 25µm and applies to all panels. n=5
mice/genotype, minimum 3 sections/mouse. *p<0.05 vs. control. #p<0.05 vs. WT.
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Herovici histological stain easily differentiates thin (blue) versus thick (pink/red)
collagen fibers of WT and SPARC-null PDL and validates PSR findings (Fig. 26D).
SPARC-null

Native

PDL

Exhibits

Disorganized

Three-Dimensional

Collagen

Morphology
Second-Harmonic Generation (SHG) microscopy is used to detecting threedimensional biological structures with high hyperpolarizability, like collagen fibers, in
fresh, non-fixed, non-decalcified, tissue samples. SHG microscopy was utilized to
highlight the morphology of PDL collagen fibers with high resolution and contrast (Fig.
27). Backward-emitted SHG imaging was conducted on fresh WT and SPARC-null
homeostatic PDL. Native SPARC-null PDL exhibits disorganized, thinner collagen fibers
compared to WT PDL (Fig. 27).

Section 3. TG controls collagen cross-links in PD.
The reductions in alveolar bone volume and PDL collagen content and
morphology in SPARC-null mice compared to WT mice suggested the importance of
ECM assembly, composition, and remodeling during PD. While we know SPARC
facilitates collagen assembly in the PDL during homeostasis and PD the mechanism
behind collagen fiber morphology is unknown. Previously, our lab has shown in
homeostatic PDL that inhibition of the cross-linking enzyme TG2 has partially rescued
SPARC-null collagen content and thickness, which translated functionally to increased
mechanical strength of the PDL. Herein we propose a mechanistic function of TG in
collagen fiber remodeling in periodontal tissues during PD.

96

WT

SPARC-null

Figure 27. Three-dimensional SPARC-null PDL collagen fibers exhibit disorganized
morphology. SHG images acquired with longitudinal sectioning of fresh, homeostatic
WT and SPARC-null PDL (age: 3 months). Images taken with 30X objective lens, zoom
2, and oriented with tooth on top, PDL centered, alveolar bone on bottom. Red pixel
coloration indicates laser saturation of collagen-rich surrounding tissues (tooth and bone)
and initiation of calcification of Sharpey’s fibers. Scale bar: 30µm.
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Increased TG2 Activity in PDL in the Absence of SPARC
Inhibition of TG in vivo partially restores mechanical strength of SPARC-null
PDL collagen fibers during homeostasis. To test the expression and cross-links mediated
by TG2 during inflammatory PD, immunohistochemistry was conducted in WT and
SPARC-null PDL following ligature treatment (5- and 14-day time points). Consistent
with increases in TG2 expression observed during other inflammatory disease states, TG2
expression significantly increases in both WT and SPARC-null PDL following 5-day
ligature compared to control PDL (Fig. 28A). WT and SPARC-null ligated PDL exhibit
similar increases in TG2 expression (Fig. 28A). Using an antibody directed against the
TG2 cross-link epitope, IHC revealed significant increases in TG-mediated cross-links in
ligated (5-day) WT PDL compared to control PDL. TG2-mediated cross-links increase
significantly further in ligated (5-day) SPARC-null PDL compared to ligated WT PDL
and controls (Fig. 28B). WT and SPARC-null PDL, following 14-day ligature, display
similar trends of increasing TG2 expression; only WT PDL shows statistically significant
increases (Fig. 28C). IHC of 14-day ligature-treated PDL reveal increases in TG2mediated cross-links in both WT and SPARC-null (Fig. 28D), recapitulating 5-day data.
TG and SPARC Protein Expressed in Human PDL Fibroblasts
Aberrant changes in TG2 and SPARC expression levels have been reported in
inflammatory disease states. To analyze TG2 and SPARC protein expression levels in
patients, human PDL (hPDL) fibroblasts were obtained from healthy and diseased (PD)
participants. hPDL fibroblasts were cultured to passage 5 and then collected for
immunoblotting. Protein extracted from hPDL fibroblasts of patient #5 (PD) and patient
#9 (healthy control) expressed both TG2 and SPARC (Fig. 29).
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Figure 28. Ligature increases TG2 expression in SPARC-null and WT PDL. TG
activity increases in ligature model in the absence of SPARC. A) Representative IHC
images of anti-TG2 following 5-day ligature; quantification of positive TG2 staining
graphed below. Scale bar: 30µm and applies to all panels. B) Representative IHC images
of anti-N-ε-γ-glutamyl lysine following 5-day ligature; quantification of positive crosslinking epitope staining shown below. N=5. C) Quantification of positive TG2 and D)
TG cross-linking epitope staining following 14-day ligature. N=3. *p<0.05 vs. control.
#p<0.05 vs. WT.
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Figure 29. Human PDL Fibroblasts Express TG2 and SPARC Protein. Western blot
for TG2 and SPARC protein in human PDL fibroblasts obtained from 1 healthy patient
and 1 PD patient. B-tubulin serves as a loading control.
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In these preliminary experiments, apparent increases in expression levels of TG2 and
SPARC are observed in hPDL fibroblasts from patient #5 suffering from PD compared to
patient #9 healthy control patient (Fig. 29). Coomassie blue staining was used for equal
loading of protein. B-tubulin was used as a housekeeping gene.
Inhibition of TG Decreases Alveolar Bone Volume Fraction Following Ligature
Following TG inhibition by BC injections (or DMSO vehicle control) for 4 days
followed by 24 hours in organ culture WT C57Bl/6 mice, maxillae were dissected and
alveolar bone volume fraction (BV/TV) was analyzed by µCT. Five-day ligature induced
significant reductions in BV/TV of maxilla in both vehicle and BC-treated groups (Fig.
30B). Interestingly, mice with ligature receiving daily injections of BC for TG inhibition
demonstrated further reductions in alveolar BV/TV compared to vehicle DMSO-injected
maxillae (Fig. 30B). Qualitative BV/TV reductions are not patently discernable despite
representative images (Fig. 30A) taken from samples exhibiting the greatest deviations in
BV/TV from the mean.
Inhibition of TG Restores PDL Collagen Content Following Ligature
Collagen fiber morphology and content of WT PDL, with and without ligature,
+/- TG inhibition with BC injections is visualized by PSR staining and Herovici staining
protocols. Red/orange polarized PSR is indicative of thick collagen fibers, while
yellow/green polarized PSR indicates thin collagen fibers (Fig. 31A). Five-day ligature
treatment significantly reduces total collagen content of PDL in both DMSO and BCtreated mice. BC injections increase total collagen content in both control and ligaturetreated PDL compared to DMSO injected counterparts (Fig. 31C).
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Figure 30. TG inhibition induces further reductions of BV/TV following 5-day
ligature compared to vehicle. A) Representative µCT images of DMSO or BC-injected
WT maxillae following 5-day ligature or control. B) Quantification of bone volume/total
volume (BV/TV) of WT maxillary alveolar bone for each treatment group. N=5
maxillae/treatment group. *p<0.05 vs. control. #p<0.05 vs. DMSO.
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Figure 31. Injection of BC increases total PDL collagen content by rescuing thick
and thin fibers following ligature. A) Representative polarized PSR-stained PDL
sections of WT mice with and without 5-day ligature +/-BC injections. Scale bar: 25um,
applies to all panels. B) Representative Herovici-stained PDL images. Pink/red =
thick/mature collagen fibers, blue/purple = thin/young collagen, yellow = reticulum/cell
death, black = nuclei. All images oriented with tooth on top, PDL center, and alveolar
bone on bottom. All ligature images taken of PDL surrounding ligated 2nd maxillary
molar. 40X magnification. C) PSR quantification percent total collagen. D) PSR
quantification thick vs. thin collagen fibers. N=5 mice/group, 5 sections/mouse. *p<0.05
vs. control. #p<0.05 vs. DMSO.
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Ligature treatment reduces percent of thin and thick fibers in both DMSO and BCinjected PDL (Fig. 31D). Interestingly, BC-injections increased both thin and thick
collagen fibers following ligature when compared to DMSO-injected PDL (Fig. 31D).
BC-injections even significantly increased thick collagen fiber content of control unligated PDL compared to DMSO-injected control PDL (Fig. 31D). Herovici-stained PDL
validated collagen finding reported by PSR. Herovici stains thick/mature collagen
pink/red, thin/young collagen blue/purple, reticulum/cell death yellow, and nuclei black.
DMSO injections induce reductions in pink thick fibers, reductions in blue thin fibers,
and increases in yellow staining indicative of cell death in both control and ligated PDL
compared to BC-injected PDL (Fig. 31B, top two panels). Herovici staining of BCinjected PDL reveals increases in both thick and thin (pink and blue, respectively)
collagen fibers, and reduced cell death (yellow) compared to DMSO-injected PDL (Fig.
31B, bottom two panels). BC-injected 5-day ligature treatment induces apparent minor
reductions in thick and thin fibers as well as slight increases in cell death (yellow)
compared to control BC PDL (Fig. 31B, right panel).
Inhibition of TG Rescues Collagen Morphology in Native PDL Following Ligature
Second-harmonic generation imaging enables the visualization of native PDL
collagen in 3-dimension. Orthogonal reconstruction of z-stacked images taken of murine
PDL +/- BC/DMSO injections following 5-day ligature provide qualitative data on
collagen morphology, organization, and fiber bundle thickness in WT mice (Fig. 32).
DMSO-injection alone induced morphological changes in collagen organization of PDL.
Five-day ligature further degrades PDL collagen fiber morphology and reduces
discernible thick fiber bundles.
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Figure 32. BC injection rescues collagen fiber morphology in native WT PDL
following ligature treatment. Representative second-harmonic generation orthogonal
images generated from z-stacks taken at 0.2µm/slice for depths of up to 60µm of native
WT PDL +/- BC/DMSO injections following 5-day ligature treatment. Apparent
increases in collagen fiber thickness and organization are observable in BC-treated PDL
compared to DMSO-treated PDL. Following ligature, reappearance of thick collagen
fiber bundles are apparent in BC-treated PDL compared to DMSO-treated PDL.
Scale bar = 20µm.
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BC-injection alone increases apparent collagen fiber thickness and total content in PDL
when compared to DMSO control. Additionally, the presence of thick collagen bundles
reappear following 5-day ligature treatment with addition of BC injection (Fig. 32).
Inhibition of TG Increases Native PDL Collagen Organization
To quantify backward SHG imaging, two-dimensional compilations of z-stack
images (Fig. 33A) were subjected to Fourier transformation, based on intensity, to
retrieve the pattern of image line directions, so as to characterize the geometry of the
image texture. The frequency distribution in a Fourier-transformed (FFT) imaged was
quantitatively calculated by fitting the result with an ellipse and by calculating the ratio
between its short and long axes, i.e. its aspect ratio (AR) (Fig. 33B). The 2D FFT
diagrams transform from circular shapes to elliptical shapes, which indicates a transition
from random patterns to organized patterns (Fig. 33B, top to bottom). The increase of the
corresponding AR is evident when moving from DMSO-treated to BC-treated PDL (Fig.
33C). It is noteworthy to emphasize the capacity of the AR to reveal transitions from
more disorganized patterns (DMSO-treated PDL) to more normal or structured patterns
(BC-treated PDL). Quantification of AR for WT (no treatment, no injection), DMSO +/ligature, and BC +/-ligature are represented in Fig. 33D.
Inhibition of TG Restores Mechanical Strength of PDL Following Ligature
Previous differences in homeostatic PDL total collagen and thick fiber content
have translated to corresponding variations in mechanical strength (Fig. 16). The partial
rescue of PDL collagen content following disease induction by inhibition of TG is
expected to translate to increased PDL strength compared to controls.
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Figure 33. Second-harmonic generation reveals increased PDL collagen fiber
organization following inhibition of TG. A) Representative stack of SHG images
(1024x1024 µm2 ROIs) taken from PDL of WT mice +/-BC/DMSO-injections following
5-day ligature. B) The FFT diagram of each representative ROI C) The calculated value
of the aspect ration (AR) of the ellipse approximating the FFT magnitude of
representative ROIs D) Graph of the mean value (+/-SD) of the aspect ration (AR) of all
4 groups with the addition of mean WT (no injection, no ligature) values for comparison.
N=6/group, *p<0.01 vs. control, #p<0.01 vs. DMSO, $p<0.01 vs. WT. No statistical
differences are reported between WT and BC control means.
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Indeed, BC-injected PDL following ligature demonstrated significant increases in the
maximum force withstood prior to tooth extraction compared to DMSO-injected PDL
following ligature (Fig. 34, black bars). Wild type and DMSO/BC control PDL without
ligature all withstood a maximum force of 5.5 newtons prior to wire failure. Therefore
differences in increased strengths between control groups are not reported and no
statistical analysis was conducted, merely the maximum force withstood by the wire is
presented (Fig. 34, white bars).
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Figure 34. BC increases mechanical strength of PDL following ligature.
Quantification of maximum force withstood by PDL prior to tooth extraction (black bars)
or apparatus wire failure (white bars). N=5 mice/group, *p<0.05 compared to control,
#p<0.01 compared to DMSO.
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS
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Section 1. SPARC and the N-propeptide of collagen I influence fibroblast
proliferation and collagen assembly in the PDL.
These results evaluated whether the N-propeptide of collagen I influences ECM
assembly and fibroblast proliferation in the PDL and if loss of the N-propeptide in
combination with loss of SPARC expression further exacerbates the defects in PDL
collagen characteristic of SPARC-null PDL. Collagen content and fiber morphology in
the PDL of exon 2-deleted and double-null mice were significantly compromised, with
double-null mice demonstrating the most significant loss of collagen at 3 months of age
(Fig. 12E and 14). The force required to extract teeth at 1 month of age was also lowest in
double-null mice versus that of either single transgenic or WT mice, indicating that the
loss of collagen content and integrity directly correlated to a decrease in mechanical
stability of the PDL (Fig. 16). Fibroblast proliferation and the number of rests of
Malassez were increased in SPARC-null and exon 2-deleted PDL with the greatest
elevations observed again in double-null PDL compared to WT PDL (Fig. 17 and 19,
respectively). Interestingly, exon-2 deleted mice demonstrated the highest level of force
required for molar extraction at 1 month of age despite reductions in collagen and thick
fiber content reported by PSR (Fig. 16). Differences in PDL collagen characterized herein
for exon-2 deleted mice are the first phenotypic alterations reported for these mice and
thus demonstrate functional significance for the N-propeptide in collagen fiber formation
in vivo.
The function of the N-propeptide in collagen biology is not well defined [140].
Mutations found in patients that either reduce or prevent processing of the N-propeptide
from collagen I give rise to malformed collagen fibrils and weaker tissue strength.
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Dermatosporaxis is a disease associated with inefficiency in processing of the Npropeptide of collagen I due to reduced or abrogated enzymatic activity of the Npropeptide proteinase, ADAMTS2/3 and 14, that gives rise to fragile skin among other
pathologies [141]. Clearly, retention of the N-propeptide of collagen I is detrimental to
collagen fiber assembly and tissue formation and is presumably mediated by interference
of the retained N-propeptide in collagen fibrils. Studies carried out in cultured cells
suggested that the N-propeptide might act as a feedback inhibitor of collagen production
[142]. As such, mice lacking the N-propeptide were anticipated to demonstrate increases
in collagen content brought about by the lack of this inhibitory function. The exon 2deleted mice were originally generated to test this hypothesis.
Bornstein et al. reported that exon 2-deleted mice lacked an overt collagen
phenotype characterized primarily at 2 months of age in skin, although there was some
embryonic lethality on specific backgrounds [136]. Similarly, our laboratory reported a
lack of phenotypic differences in adult skin of exon-2 deleted mice [135]. However,
when coupled with a lack of SPARC expression, robust differences in dermal collagen
content and morphology were found in SPARC-null/exon-2 deleted mice over and above
that of SPARC-null mice, perhaps suggesting a cooperative role of SPARC and Npropeptide. In contrast to skin, at 1 month of age the PDL of exon-2 deleted mice
displayed decreased total collagen and increases in thin fibers (Fig. 12E and 14).
Interestingly, this collagen phenotype appeared to recover in the exon-2 deleted PDL by
the 12-month age point. Perhaps, a compensatory mechanism supported by other
collagens present in the PDL of exon-2 deleted mice mediates recovery. In addition to
type I, type III collagen is highly expressed by human gingival and PDL fibroblasts
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[143]. The N-propeptide of procollagen III is synthesized in a very comparable pattern to
that of procollagen I and has similarities in sequence and structure to the N-propeptide of
collagen I [144]. Hence, functional redundancy of the N-propeptide of procollagen III
might compensate for the lack of the type I N-propeptide in the exon-2 deleted mouse
and explain the collagen I phenotypic recovery observed in these mice at later time
points. We also speculate that the high rate of collagen turnover in the PDL affords the
opportunity to discern functional activities of the N-propeptide that might be more subtle
in tissues with slower collagen turnover such as the skin.
Few published reports characterizing collagen fiber analysis by Herovici stain are
available. Reynolds et al. reported that collagen fibers, when treated with collagenase,
undergo changes in Herovici stain color from red to blue. In addition, tissues with higher
levels of thin collagen fibers, such as embryonic and those with healing wounds,
demonstrate increases in blue stained collagen fibers over red fibers [145]. In our hands,
differences in blue and red-stained fibers are evident in 1- and 12-month murine PDL.
Particularly, the exon-2 deleted 1 month PDL (Fig. 15B) that displays an apparent
increase in red-stained fibers, compared to WT, that can be observed weaving into tooth
and bone. Herovici staining might provide an improved method for visualizing thin
collagen fibers, particularly in the PDL, versus PSR because of the inherent strong PSR
signal from surrounding collagen rich tissues (bone and tooth). In contrast to other soft
tissues, not surrounded by collagen-rich mineralized tissues, the distinction between thick
and thin collagen fibers in the PDL can be challenging by PSR histology. An increase in
thick collagen fibers in exon-2 deleted mice visualized with Herovici stain would be
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consistent with increases in mechanical strength observed in these mice at a month of
age.
At 1 month of age, the mechanical strength of the double transgenic SPARCnull/exon-2 deleted PDL was significantly decreased compared to all other genotypes as
evidenced by the decrease in force required for molar extraction (Fig. 16). This result is
in line with the decreased collagen content and fiber thickness observed histologically.
The exon-2 deleted mice were the only transgenic line studied that displayed increased
mechanical strength of PDL compared to WT, a surprising result based on the reduced
amount of collagen I observed at 1 month versus WT mice. A possible explanation is that
subtle differences in collagen structure might exist in the exon-2 deleted PDL that
account for increases in strength of the ECM in the absence of overt differences in
collagen fiber morphology or content. For example, changes in ECM structural properties
originating from alterations to collagen cross-linking could contribute to the increased
mechanical strength of the PDL observed in exon-2 deleted mice. Future experiments to
understand how ECM composition might alter mechanical properties of the PDL should
be enlightening.
Fibroblast proliferation, as measured by Ki67 positive cells, was increased in the
PDL of both single-transgenic mice. The increase in proliferation was further exaggerated
in double-null PDL compared to single transgenics and WT (Fig. 17 and 18). Fibroblasts
are known to bind and respond to growth factors sequestered in the matrix, particularly
during wound healing [146]. In an ECM environment characterized by decreased
collagen content such as that of the transgenic mice, factors normally sequestered, for
example fibroblast growth factor-2 (FGF-2), might be present in higher concentrations as
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active, soluble factors that stimulate fibroblast proliferation versus WT PDL. Perhaps the
increase in fibroblast proliferation might represent a compensatory mechanism to
replenish the lack of collagen content in double-null PDL, for example.
Epithelial Rests of Malassez (ERMs) were also increased in the PDL of transgenic
mice (Fig. 19). ERMs are cell clusters from Hertwig’s epithelial root sheath (HERS) that
remain in the PDL after root formation is complete. ERMs are known to proliferate and
increase in size under conditions of PDL stress, such as orthodontic tooth movement, but
their functional role in the ECM is poorly understood [147]. ERMs are capable of
undergoing epithelial-mesenchymal transition and differentiate into various cell types
[148]. These cell rests are speculated to play a role in regeneration and repair of the
periodontium. The increase in number and area of these rests observed in singletransgenic mice and further exaggerated in double-transgenic mice could serve as an
indicator of a stressed and weakened PDL. As each of these transgenic mice displayed
decreases in thick collagen and increases in thin collagen, one might speculate that each
also has increased tooth movement during mastication. The increases in tooth movement
resulting from a weaker PDL might explain the increase in ERMs observed in transgenic
mice when compared to WT. ERMs are also known to proliferate with age in homeostatic
murine PDL [149]. Cell adhesion and proliferation potentially contribute to epithelial cell
rest proliferation and growth within the PDL matrix. However, Yan et al. reported no
differences in lens epithelial cell proliferation in the absence of SPARC compared to WT
in vivo [150]. Since the absence of SPARC does not affect epithelial proliferation
globally, we do not highlight epithelial cell expansion as a main factor altering the ERMmatrix structure. The increased presence of ERMs in 12-month WT PDL is attributed to
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aging PDL turnover and remodeling. The significant increase in SPARC-null rests at 12
months compared to WT correlates with the decrease in total collagen content (Fig. 12E)
and a decrease in the amount of thick fibers present in 12-month PDL (Fig. 14). We
hypothesize the failure of SPARC-null PDL to recover collagen content at 12-months
indicates a stressful/weakened ECM resulting in further ERM proliferation. Interestingly
the recovery of the collagen phenotype observed in exon-2 deleted PDL at 12 months
(Fig. 12E and 14) is reflected in a decrease in the number and area of ERMs occupying
the PDL at this age. Double-null PDL at 12 months, was shown to have substantial
decreases in collagen content and morphology likely resulting in a robust proliferation of
both number and size of ERMs (Fig. 19I and J).
Surprisingly, the BV/TV of exon-2 deleted mandibles was the lowest of all 4
genotypes tested whereas SPARC-null single transgenics had increased BV/TV at 1
month of age versus wt/wt (Fig. 20E). Previously, our laboratory reported reductions in
mandibular BV/TV at 4 months in SPARC-null mice consistent with overall reductions in
SPARC-null mice characteristic of an osteopenic phenotype [67, 117]. These results
indicate that the absence of SPARC expression does not primarily influence bone
deposition during mandible development but is required for bone maintenance over time,
in line with studies from other types of bone in SPARC-null mice [77]. The fact that
exon-2 deleted mandibular bone demonstrated significant decreases (Fig. 20E) compared
to other genotypes suggests a role of the N-propeptide in bone development, the
mechanism of which will be the subject of future studies. Possibly, expression or
localization of other ECM proteins known to participate in calcification of bone matrix,
such as osteopontin, might be altered in exon-2 deleted mice.
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We conclude that the absence of SPARC expression combined with a lack of the
N-terminal propeptide exon 2 altered collagen type I morphology, cellularity, and
mechanical stability of the PDL. The mechanisms behind the activities of both SPARC
and the N-propeptide of collagen I need further exploration and could provide insight into
collagen assembly and ECM remodeling. Further studies will highlight potential targets
in the pathway of collagen assembly and regeneration, applicable to tissues suffering
from collagen deficiency or following an injury disease state such as PD.
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Section 2. Ligature-induced PD induces greater loss of periodontal tissues and alters
monocyte-derived cellular response in SPARC-null mice.
Previous characterization of SPARC-null PDL in response to lipopolysaccharide
injection revealed deficiencies in total collagen volume fraction and collagen fiber
thickness. Alveolar bone loss associated with LPS injections was greatly increased in the
absence of SPARC [117]. Since LPS injection is criticized as a model of PD for the lack
of bacterial colonization and allowance for natural disease progression, we implemented
a ligature-induced model of PD to assess the role of SPARC on collagen catabolism,
alveolar bone turnover, and monocyte-derived cellular response to inflammation over
time. Alveolar bone loss associated with ligature-induced PD increased in SPARC-null
mice in comparison with WT mice after 5 days (Fig. 21C). Following a longer 14-day
ligature disease model, reductions in alveolar bone volume were non-significant in WT
mice, whereas SPARC-null reductions persisted (Fig. 21D). The increased loss of bone in
SPARC-null mice was not surprising, since these mice develop osteopenia characterized
by decreased bone mineral density in long bones [67]. Interestingly, the persistent
reductions in SPARC-null alveolar bone at the 14-day time point suggest contributory
factors of intrinsic differences in ECM in determining PD outcomes.
In addition to reductions in mineralized periodontium, decreases in fibrillar PDL
collagen were reported in SPARC-null mice at 5- and 14-day ligature time points (Fig.
26). Consistent with alveolar bone volume increases following 14-day ligature, WT PDL
total collagen content returned to baseline levels (Fig. 26C and F). We attribute the
increased collagen content to significant increases in thin, newly formed fibers consistent
with a remodeling matrix. We attribute the absence of an increase in thin fiber content in
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SPARC-null PDL largely to the inherently higher thin fiber content composition of PDL
during homeostasis, characteristic of SPARC-null mice. Deficiencies in dermal
procollagen processing and decreased collagen deposition in ECM have been reported in
SPARC-null mice [55, 151]. Additionally, high expression levels of SPARC are
correlated with states of matrix remodeling and tissue turnover such as developing
embryonic tissues, would healing, and fibrotic disease conditions [41, 152, 153]. Thus,
the reductions in collagen content in SPARC-null PDL might result from deficient
collagen deposition in response to the ECM remodeling that occurs following injury.
Previous reports from our laboratory have described general reductions in
inflammatory cells following LPS challenge in SPARC-null PDL [117]. Importantly, we
observed no differences in circulating inflammatory cells in SPARC-null mice (Fig. 24),
suggesting that recruitment or persistence of macrophages in tissue was dependent on
SPARC rather than hematopoietic events. Ligature-induced PD resulted in robust
expression of F4/80+ macrophages in WT PDL with a muted expression in SPARC-null
PDL (Fig. 22). Macrophages, unlike neutrophils, are known to express SPARC, which
aids in endothelial extravasation [152]. Again, we report increased persistent
inflammation in SPARC-null PDL with a reduced number of macrophages present (Fig.
22). The alterations in ECM in SPARC-null PDL could be limiting macrophage
recruitment to the area of disease induction. An alternative hypothesis is that although
there are reduced numbers of macrophages present, these could be more potent matrixdegrading macrophages versus more matrix-repairing macrophages observed in WT
PDL. Further investigation into macrophage polarization and/or recruitment in SPARCnull inflammatory states could elucidate mechanisms specific to SPARC-null
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macrophages that differ from WT. Reports of SPARC-null mice with dextran sodium
sulfate (DSS) induced colonic inflammation also demonstrated reduced levels of
monocytes, neutrophils, and macrophages at the site of inflammation when compared to
WT mice [154]. However, a study conducted in SPARC-null dermal inflammation
reported opposite results wherein the mice demonstrated increased inflammatory cell
movement and recruitment through the looser collagenous ECM of SPARC-null mice
compared to WT mice [155]. Therefore, the implications of SPARC during inflammation
appear to be tissue-specific.
Since macrophages and osteoclasts derive from the same monocyte precursor cell,
the outcomes from our TRAP-staining were not surprising, as they recapitulated our
F4/80+ macrophage results (Fig. 23). Interestingly, the fewer osteoclasts observed in
SPARC-null mice is counterintuitive to the reductions in bone volume compared to WT
mice characterized by robust osteoclast staining. Characterization of the SPARC-null
osteopenic phenotype reported inherent reductions in osteoclast and osteoblast number
and surface area. Of particular interest was the variation in distribution of the TRAP+
osteoclasts. Following 5-day ligature treatment, both WT and SPARC-null mice had
significant increases in TRAP+ cells present in the PDL itself, not in contact with bone or
tooth. Osteoclasts at the classic location of bone:PDL interface were reduced only in
SPARC-null mice (Fig. 23E). By the 14-day time point the numbers of TRAP+
osteoclasts were greatly reduced compared to the 5-day time point in both WT and
SPARC-null mice (Fig. 23D). The distribution of these osteoclasts were unchanged in
SPARC-null mice following ligature, compared to control and compared to WT
osteoclast distribution (Fig. 23F). The change in osteoclast number and distribution after
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a longer state of inflammation at the 14-day time point compared to results of the 5-day
ligature time point, suggests differences in the healing response of SPARC-null
periodontium compared to WT periodontium. One study conducted a longer ligature
time-course utilizing additional time-points of: 3-, 7-, 11-, 15-, and 21-days of ligature in
male Wistar rats followed by µCT analysis of alveolar bone volume fraction at each time
point. Rats were reported to have maximum alveolar bone loss at the 11-day time point
following ligature treatment. By 21 days of ligature, the alveolar bone volume of rats
returned to non-significant levels compared to control alveolar bone (no ligature
treatment). The study correlated levels of alveolar bone loss directly with temporal
expression of matrix metalloproteinases 8 and 13, both of which are found in human
gingiva and crevicular fluid during PD. Specifically, MMP-13 immunoreactivity was
localized in an increased number of osteoclasts from day 7 to day 11 of ligature treatment
[156]. However, there are many additional MMP family members (1, 2, 3, 7, 9, and 10)
with ECM substrates that are associated with PD outcomes in human patients [157].
Specifically, increased levels of MMP-2, -3, and -9 have been reported in epidermal,
cardiac, and ocular tissues of SPARC-null mice compared to WT mice, respectively [154,
158, 159]. A longer experimental ligature time course and characterization of the MMP
profile in periodontal tissues (PDL and alveolar bone) could provide further insight into
mechanistic differences contributing to osteoclast variation between WT and SPARCnull mice.
One theory in PDL biology focuses on the potential of the PDL to house resident
mesenchymal stem cell populations. These “PDL stem cells” are thought to be capable of
differentiating toward macrophage/osteoclast cell types and aiding in regeneration of
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periodontal tissues [160]. Studies have shown that under orthodontic tooth movement,
during which the PDL is under a state of increased mechanical tension and ECM
remodeling, that these “PDL stem cells” produce hydrogen sulfide (H2S) which induces
secretion of monocyte chemoattractant protein-1 (MCP-1) and expression of receptor
activator of nuclear factor-κB ligand/osteoprotegerin (RANKL/OPG) system. The
secretion and expression of these factors was directly implicated in macrophage
migration and osteoclast differentiation and led to differences in regulating the rate of
alveolar bone turnover [161]. SPARC-null mice have no detectible differences in the
number of stem cell populations compared to WT mice, only differences in the
capabilities of these cells to differentiate towards various cell types [75]. However,
intrinsic differences in SPARC-null ECM could affect the ability of these “PDL stem
cells” to differentiate and/or migrate towards the alveolar bone, particularly since the
ligature model increased the numbers of osteoclasts embedded in the PDL and reduced
the numbers in contact with the ruffled border of the alveolar bone compared to the
location of WT osteoclasts. Further characterization of differences in cytokine profiles of
SPARC-null and WT mice in response to ligature-induced inflammation will provide key
insight into specific mechanisms altering the macrophage and osteoclast response in the
periodontium.
The high expression level of alkaline phosphatase (ALP) observed in the PDL of
WT control mice was not surprising since PDL cells in vitro have been shown to possess
high constitutive levels of ALP activity (Fig. 25). Osteoblasts have been reported to
express large amounts of ALP, that contribute to osteoblast differentiation, when
stimulated by bone morphogenic protein-2 (BMP-2) in human PDL (hPDL) cells grown
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in vitro [162]. Current literature lacks reports of ALP expression variations in SPARCnull compared to WT expression levels. Again, we know from the osteopenic phenotype
characterization in SPARC-null long bones that, in addition to reductions in osteoclast
cell numbers and surface area, these mice also exhibit reductions in osteoblast cell
number and surface area [67]. The osteopenic propensity of SPARC-null cranial bones
has yet to be reported, but it would be logical to expect similar reductions of OBs and
OCs as seen in the long bones. Since the reduced levels of ALP expression in SPARCnull PDL did not change following 5-day ligature, we chose not to focus on the osteoblast
cell type in determining PD outcomes in our model. Thus, we did not conduct ALP
staining on samples from the 14-day ligature time point. No significant differences in
mRNA expression of other markers of osteoblast differentiation: osteocalcin (OCN) and
osteopontin (OPN), were reported in SPARC-null long bones compared to WT RNA
levels [67]. Future characterization of mRNA and protein levels of osteoblast-associated
markers (ALP, OCN, OPN, and osterix) in SPARC-null periodontium will help to
corroborate the altered PD phenotype reported in our ligature model.
In human PD, degradation of PDL collagen and alveolar bone is associated with
persistent inflammation. Failure of the host immune response to resolve inflammatory
mediators resulting in continued tissue damage is an essential determinant of PD
outcomes. Our results suggest that intrinsic differences in ECM composition impact the
host ability to respond, repair, and resolve PD. Additionally, our results implicate the
potential predisposition of genetic mutations contributing to alterations in ECM
assembly, collagen morphology, and alveolar bone biology, as major determinants of PD
outcomes. Of future interest is investigating specific SPARC-expressing cell types
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involved in exacerbating the PD phenotype, as well as the potential modulation of
SPARC protein to alleviate chronic inflammatory states. Findings from future studies
could highlight key molecular and/or genetic targets for diagnosis of clinical
predisposition to severity of PD and regenerative periodontal treatments.
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Section 3. TG controls collagen cross-links in PD.
Given the increased susceptibility to alveolar bone loss, deficits in collagen
content, and aberrant changes in monocyte-derived cellular responses in the periodontium
of SPARC-null mice, cellular mechanisms of collagen and ECM response in PD merited
investigation. Insoluble collagen cross-links are a key aspect contributing to proper
collagen assembly and morphology, incorporation into the ECM, and maintenance of
tissue integrity. Data previously published by our laboratory have implicated the function
of the cross-linking enzyme, TG, in fibrillar collagen assembly and regulation by SPARC
in homeostatic PDL [66]. We report herein increases in immunostaining for TG2 and for
N-ε-γ glutamyl lysine, the cross-link catalyzed by TG, in PD. PD in the absence of
SPARC results in increased activity of TG2 in PDL, characterized by cross-link
formation, over that of WT PDL. We demonstrate, for the first time, the expression of
both TG2 and SPARC protein in human PDL fibroblasts from both healthy and diseased
patients. Apparent increases in both TG2 and SPARC protein levels implicate
mechanistic functions in human disease states. Inhibition of TG decreased alveolar bone
volume fraction in WT mice (Fig. 30). Circulating TG, Factor XIII-A, is implicated in
osteoblast differentiation [83]. Reductions in alveolar bone volume following treatment
with a pan-TG inhibitor, are hypothetically due to inhibition of Factor XIII-A. Direct
targeting of tissue TG2, would potentially alleviate the reported bone phenotype.
Differences in PDL collagen morphology in PD, most notably the reductions in collagen
fiber size and total amounts of collagen, were rescued by inhibition of TG activity in
vivo. Visualization of native collagen morphology, by second-harmonic generation
imaging, following disease and TG inhibition, exhibited restoration of PDL collagen
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content and morphology viewed in 3-dimensions. The subsequent restoration of PDL
fibrillar collagen morphology by inhibition of TG, functionally translated to increases in
mechanical strength of PDL after disease. Our data provide evidence for a function of TG
in fibrillar collagen regeneration in vivo following destruction mediated by PD.
TG family members catalyze ECM cross-linking, a function that is implicated in
stabilizing and cross-linking proteins. In addition to forming insoluble protein complexes,
a critical function of TG in ECM collagen fiber assembly in vivo was established by our
laboratory. Increased TG activity, in homeostatic PDL, resulted in the formation of
smaller collagen fibrils and inhibition of TG activity increased total amounts of collagen,
fibril diameter, and restored mechanical strength in both WT and SPARC-null mice [66].
Previous reports have shown that the expression and activity of TG is increased in
various tissues during inflammatory disease states (neurodegenerative, autoimmune,
intestinal inflammation, cancers) [163]. Increases in TG expression were reported in
human patients experiencing gingival overgrowth [128, 129]. However, the mechanism
of up-regulation and the physiological role for TG in the inflammatory process is poorly
understood.
There is evidence that TG2 prolongs the inflammatory phase of tissue healing. TG
initiates a more aggressive inflammatory response by up-regulating TGF-β1 activation,
enhancing phospholipase A2 activity through polyamination, and increasing macrophage
phagocytosis [164]. Matarese et al. demonstrated increased TG2 mRNA levels in
cultured hPDL cells from PD patients and showed the capability of TG2 to promote the
activation of NF-κB by cross-linking it’s inhibitor: Iκ-βα. Reductions in TG activity in
human THP-1-differentiated macrophages were concomitant with the loss in NF-κB
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activation and reduction in RANKL expression. The authors concluded that TG2 initiates
inflammation through the TG2/NF-κB interplay, which activates inflammatory cells by
increasing RANKL expression in the PDL of periodontal diseased patients [134]. Similar
to other matrix components that are induced following tissue injury, TG2 expression is
increased through up-regulation of mRNA via cytokine induced transcriptional increases
mediated by factors such as: TGF-β, TNF-α, IL-6 in tissues such as skin and liver [165167]. Of interest to our study are the implications of TG in remodeling of PDL collagen
during PD. Our current results show that PD was associated with increased TG2
expression and activity in PDL (Fig. 28), consistent with previous results in other tissues
and inflammatory states. We hypothesize that the increase in TG2 expression and activity
during PD is attributed to up-regulation of the promoter region by inflammatory
cytokines.
SPARC is an established substrate of TG, acting as a glutamine donor [80]. We
report further increases by immunohistochemistry for N-ε-γ glutamyl lysine cross-link,
following PD in SPARC-null over that observed in WT PDL (Fig. 28). Previously, our
lab has shown no differences in baseline TG activity in PDL and liver from WT and
SPARC-null mice by in vitro assays. Total protein extracted from SPARC-null PDL
exhibited increased incorporation of a TG substrate (biotin cadaverine) versus WT [66].
These results suggest that SPARC does not directly inhibit the enzymatic activity of TGs,
but instead alters the substrate specificity in the ECM. While TG expression is upregulated by inflammatory PD, the absence of SPARC increases the available TG
substrates and allows for further TG-mediated cross-links compared to WT PD.
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To further validate our hypothesis of TG activity contributing to collagen crosslinks during disease we conducted a series of experiments to inhibit the action of TG in
vivo. Initially, in vivo TG inhibition in experimental PD was conducted only in WT mice
to test validity as a therapeutic target in human disease. Inhibition of TG activity
increased total amounts of PDL collagen and fiber thickness following PD in our WT
mice (Fig. 31). We were able to confirm the 3D structure of native, fresh PDL collagen
using SHG imaging (Fig. 32). The rescued collagen morphology following TG inhibition
translated to functional increases in mechanical force required for molar extraction (Fig.
34).
Generally, increases in collagen cross-links have been associated with increases in
mechanical strength and increases in tissue stiffness [168]. Hence, inhibition of TGdependent cross-linking associated with increased mechanical strength of a tissue might
appear counterintuitive. However, increased collagen-cross links mediated by TG have
been linked to reduced fiber thickness and reductions in mechanical strength of
homeostatic PDL [66]. Therefore we conclude that smaller collagen fibers provide less
mechanical strength regardless of increased cross-linking. The question of how collagen
cross-links directly impact mechanical strength and stiffness is complex. For example,
Fessel and colleagues recently reported that increases in tissue strength and stiffness
frequently associated with increases in advanced glycation end-product (AGE) crosslinks did not impact stiffness of individual collagen fibrils in tendon. Differences in
molecular sliding between supramolecular collagen structures were identified as an
important factor in mediating the effects of AGE-modified collagen cross-links [169].
Willems et al. reported that a 300-fold increase in mature collagen pentosidine cross-links
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in mandibular condyle cancellous bone did not alter bone tissue stiffness by
nanoindentation [170]. Hence, the nature of the molecular basis by which TG activity
determines collagen fiber thickness and mechanical strength will be insightful. Our
results are the first reports of morphological and functional rescue of PDL collagen
following disease.
Somewhat surprisingly, TG inhibition increased alveolar bone loss in our model
(Fig. 30B). Factor XIII-A, the plasma form of TG, is known to increase osteoblast
differentiation in vitro cultures. Additionally, mice lacking TG2 and Factor XIII-A have a
reduction

in

bone

mass

retention

in

long

bones.

Increased

adipogenesis,

osteoclastogenesis, and decreased integration of plasma fibronectin into bone matrix were
characteristics of double-null skeletal phenotype. Up-regulation of TG1 expressed by
monocytes and osteoclasts during osteoclastogenesis in double-null mice suggested a
compensatory mechanism in regulating long bone mass [171]. Since BC is a pan-TG
inhibitor, the reduction in bone volume fraction after BC injection would suggest similar
roles for Factor XIII-A, TG2, and TG1 in the cranial skeleton. We hypothesize that
specific targeting of tissue TG (TG2) and not Factor XIII-A, would restore the PDL
collagen without decreasing alveolar bone volume since Factor XIII-A is thought to be
the most important TG for bone turnover. TG2 specifically is implicated in cross-linking
glial peptides of gluten and contributing to celiac disease [172]. Therefore, there are
commercially available inhibitors of TG2. ZED1227, a peptidomimetic resembling an
acyl-donor substrate with high affinity for the active site of TG2, is currently in clinical
trials for therapeutic potential [173]. Perhaps the use of ZED1227 would be a better TG
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inhibitor alternative to BC in restoring collagen content and morphology following PD
without causing adverse affects in alveolar bone.
Mechanisms underlying increased TG2 expression during induction of
inflammation are attributed to up-regulated mRNA via the promoter region and cytokine
response. The literature lacks reports of alterations in TG expression/activity in the
proliferative and remodeling phases of inflammation. Results from inhibition of TG
implicate TG in tissue ECM remodeling during inflammatory PD. We were able to show
restoration of collagen morphology, thick fibers, and total content in diseased PDL,
which translated to increases in mechanical strength of the tissues. Further investigation
of TG2-specific targeting will give insight into the potential use of TG as a directed
therapy in collagen biology in tissue remodeling following inflammatory destruction and
fibrotic disease states.
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FUTURE DIRECTIONS
There are several unanswered questions that should be addressed in the future.
First, it is important to study the mechanism by which SPARC regulates TG’s crosslinking activity in fibrillar collagen. Our central question focuses on the binding capacity
of SPARC on collagen I to direct TG modification. The SPARC binding site on collagen
is well established. Cyanogen bromide (CB) fragmentation of the collagen α1(I) strand
did not result in significant changes in TG modification between WT and SPARC-null
mice, implicating that the modifications of this strand were not dependent on SPARC
binding to collagen (Bradshaw & Trombetta-eSilva, unpublished). However, CB
fragmentation of the collagen α2(I) strand revealed apparent differences in TG
modifications that did not correspond to mapped SPARC binding sites (Bradshaw &
Trombetta-eSilva, unpublished). Future studies using mass spectroscopy to further
analyze CB-generated collagen fragments will identify TG-modified residues. These
experiments will facilitate the identification of specific glutamine residues involved in
TG-mediated modifications and cross-links of collagen I. Directed inhibition of TG2 in
SPARC-null compared to WT PDL will experimentally confirm the results from mass
spectrometry.
TG catalyzes another reaction independent of collagen cross-linking that involves
the covalent addition of free amines to glutamine residues. One such free amine present
in vivo known to be modified by TG is serotonin [174]. Collagen modification by
serotonin is unknown. Perhaps collagen is modified by serotonin and this modification is
dependent on the presence or absence of SPARC. Since BC not only acts as a TG
substrate but also as a free amine, there is potential for BC to block the serotonylation of
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collagen in our model in vivo. It is widely known that patients taking selective serotonin
reuptake inhibitors (SSRIs) have reduced bone turnover and impaired healing leading to
more severe PD outcomes [175]. Mechanisms attributed to reductions in bone quality and
increased fracture rates regarding the use of SSRIs are vastly unknown. Serotonin
receptors and transporters have been identified on osteoblasts, osteoclasts, and osteocyte
cell lines [176]. Interestingly, serotonin inhibits Factor XIII-A-mediated plasma
fibronectin matrix assembly and crosslinking in osteoblast cultures by directly competing
with FXIII-A transamidation reactions. In addition to a discontinuous pFN matrix,
treatment of osteoblast cultures with serotonin resulted in impaired collagen deposition,
mineralization, and lysyl oxidase activity [177]. Collagen and thrombin-activated
platelets (COAT) are activated by TG2 and Factor XIII-A and link peripheral serotonin to
procoagulant proteins enabling fibrinogen/thrombospondin bonding to the platelet
surfaces [178]. Taken together, these data suggest that TG2/Factor XIII-A are important
factors regulating serotonin binding to collagen. Future studies determining
serotonylation of collagen and potential differences between WT and SPARC-null
collagen modification will provide insight into TG-mediated activity, in addition to crosslinking, contributing to changes in ECM. Results from these studies could be highly
useful in studying ECM remodeling in vivo, particularly in PD.
Much attention has focused on macrophages in mediating the transition between
inflammation and repair. Macrophages are known to express SPARC to aid in
extravasation through endothelium during states of cardiac fibrosis and repair [152].
SPARC is thought to mediate cardiac inflammation by favoring an M1 macrophage
phenotype while depressing markers of M2 macrophages [61]. Up-regulation of TG2

132

mRNA was correlated with increased levels of inflammatory markers IL-6, TNF-α, and
HMGB-1 in THP-1-differentiated macrophages. TG2 inhibition reduced RANKL
expression in macrophages [134]. Mice lacking TG2 exhibit macrophages deficient in
clearance of apoptotic cells [179]. Our results herein indicate differences in PDL
macrophage presence in WT and SPARC-null mice following ligature. Since our reported
flow cytometric analysis indicated no differences in hematopoietic cell populations
between WT and SPARC-null mice further investigation into ECM remodeling and
macrophage response is warranted. Differences could be due to impaired macrophage
recruitment in altered ECM environments of SPARC-null compared to WT PDL. Lineage
tracing experiments using bone marrow transplants from GFP-labeled mice into SPARCnull mice and SPARC-null bone marrow transplanted into WT mice will provide
information on cell recruitment to site of disease or cell activation. If no differences are
observed between SPARC-null and WT macrophage recruitment, it is possible that the
phenotype of macrophages present are different. Perhaps SPARC-null macrophages in
PDL favor a M1 phenotype, similar to what was observed in cardiac tissues, over that of
an M2 phenotype. Analysis of secreted factors indicative of different macrophage
populations will be insightful. In vitro bone marrow-derived macrophage polarization
conducted using bone marrow isolates from WT and SPARC-null following PD
induction could indicate differences in preferential macrophage populations between
mice in response to disease. To further assess how SPARC and TG2 affect the
inflammatory response, cultured macrophages could be stimulated with SPARC and TG2
and then mRNA levels could measure secreted pro- and anti-inflammatory cytokine
profiles.
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CONCLUSION
Experiments reported in this thesis have shown that both SPARC and the Npropeptide of collagen I are critical for collagen homeostasis in healthy PDL. This is the
first report of a functional role of the N-propeptide, in isolation, in collagen cellularity
and PDL tissue integrity. In disease, the absence of SPARC leads to increased severity of
alveolar bone loss and PDL collagen degradation. Data described herein demonstrate, for
the first time that inhibition of TG is associated with change in collagen fiber morphology
and likely contributes to PD severity. Furthermore, significant changes mediated by PD
in collagen fiber content, morphology, and mechanical functionality in WT PDL were
restored by inhibition of TG activity in vivo. Thus, we present evidence in support of a
critical role of both SPARC and TG in the regulation of collagen I fiber assembly. These
results have broad implications for strategies for, not only PDL collagen regeneration, but
also broadly for collagen rich-tissues following inflammatory and fibrotic disease states.
Further studies will aim to address the mechanisms of SPARC in TG-mediated activity.
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